Funding opportunities for southern Ontario organizations

On February 27, 2019, over $1 billion was announced for FedDev Ontario to continue driving innovation and growth in the region over the next six years. Recognizing the vital role smaller and rural communities play in the region’s economy, as well as their unique needs and opportunities, FedDev Ontario is dedicating $100 million of this new funding to support projects in rural southern Ontario.

FedDev Ontario is now accepting applications under three simplified funding streams that are easy to navigate, and have been designed to meet the needs of our innovators, job creators and communities.

FedDev Ontario is looking for innovative projects in southern Ontario that will:
- Increase the number of high-growth firms.
- Strengthen key clusters and build on areas of regional innovation strength.
- Increase the commercialization of new and innovative technologies, products or processes.
- Increase business investments in the adoption/adaptation of leading-edge technologies.
- Create and maintain highly skilled jobs.
- Increase the value of exports.
- Promote inclusive growth and participation of traditionally underrepresented groups such as women, Indigenous and young entrepreneurs.
- Strengthen opportunities and networks to drive growth, and support the attraction and retention of businesses and talent to southern Ontario’s smaller communities and rural areas.

Applications can be submitted for:
- Non-repayable contributions from $250,000 up to $5 million per project for not-for-profit organizations.
- No interest, repayable contributions from $250,000 up to $5 million per project for incorporated businesses, including Indigenous businesses.

Explore our funding opportunities by clicking here and choosing one of three funding streams.

MITACS – leveraging partner funds to source funds for trainees

While the MITACS program has been around a long time, it has undergone some significant changes to both programs and structure, and it is an underutilized source for funding trainee experiences. Consider leverage your existing partnered funding to apply for added funds for trainee management, travel and collaborative programs. Ongoing applications, simplified submission procedures, and high success rates!
- Eligible partners include companies (anywhere in the world!) and not-for-profits (Canada)
- Get funding for projects big or small (4 months to 4 years or longer)
- Funding includes both stipends and research expenses

Connect with MITACS specialist Ryan Caldwell, rcaldwell@mitacs.ca located at McMaster Industry Liaison Office (MILO). https://www.mitacs.ca/en/programs

Host a Clinical Trials Intern

Western University’s Clinical Trials Management post-degree diploma is now recruiting hosts and sites for summer practicums. If you are interested in more information, please connect with Katrina Mcintosh, Katrina.mcintosh@uwo.ca, 519-661-2111 x85211, or check out further details at http://hostanintern.uwo.ca.
The Clinical Trials Management program is a one-year post-degree program that includes 9 clinical trials courses and a mandatory practicum. Enrollment is competitive and candidates must have an undergraduate Science or Health Science degree. In order to graduate from the program, students must complete a 400-hour practicum which is scheduled to run from May – August, 2019 (end dates vary based on hours/week at the site, which is flexible).

**MIRA 2019 Funding**

**TRAINEE FUNDING**

**MIRA Graduate Student Travel Awards**

**Deadlines to apply:** September 6  
**Funding available:** Up to 10 awards of $500

Graduate students travelling to collect data or to present research at an academic conference are eligible for up to $500 in travel funding from MIRA. For more details, [click here](#); [Download the application form here](#).

**MIRA Postdoctoral Fellowships**

**Deadline to apply:** May 1  
**Funding available:** Up to three awards of $50,000; requires supervisor match of at least $10,000 for benefits

Prospective post-doctoral Fellows are invited to submit a research plan that focuses on interdisciplinary, impact-driven approaches in the study of optimal aging through one or more of the following themes: 1) impact of exercise on mobility; 2) interrelationship between psychological function and social function; 3) causes and consequences of multimorbidity, frailty, and polypharmacy; 4) role of caregiving, equity, economics and transportation in optimal aging; 5) understanding the biological mechanisms of diseases of aging; 6) evaluating approaches to knowledge translation to improve optimal aging; and, 7) use of technology to promote optimal aging and aging in place. The applicant and principal supervisor are expected to involve at least two other researchers from two different McMaster Faculties (outside of the principal supervisor’s Faculty) as mentors in the development of an interdisciplinary research plan. For more information, [click here](#); [Download the application form here](#).

**Labarge Graduate Scholarships in Mobility in Aging**

**Deadline to apply:** May 15  
**Funding available:** One award each of $15,000 (Master’s) and $18,000 (PhD)

Students beginning a new graduate degree are eligible to apply for the Labarge Graduate Scholarship. The student’s research focus must be related to aging and mobility, and requires both a MIRA supervisor and a mentor from a Faculty outside of the supervisor’s. For more information, [click here](#).

**AGE-WELL/MIRA Co-Funded Trainee Awards**

**Anticipated deadline:** May 31  
**Available funding:** Master’s level $15,000, PhD level $18,000, Postdoctoral $50,000

MIRA and AGE-WELL have partnered to co-fund awards for trainees who are working to drive innovation and create technologies and services that benefit older adults and caregivers. Projects must fit within AGE-WELL’s vision to harness and build upon the potential of emerging and advanced technologies in areas such as artificial intelligence (AI), e-health, information communication technologies (ICTS), and mobile technologies to stimulate technological, social, and policy innovation. Funding period is September 2019 - March 2020. To be eligible for this funding, McMaster applicants must notify MIRA research coordinator Audrey Patocs ([patocsae@mcmaster.ca](mailto:patocsae@mcmaster.ca)) of their intent to be considered for the award. [More information](#).

**RESEARCH GRANTS**
## Catalyst Grants: MIRA & Labarge Centre for Mobility in Aging

**Deadline: April 30**

**Funding available: $40,000 over one year; six grants available (one per McMaster Faculty)**

MIRA/Labarge Catalyst grants offer the opportunity to conduct collaborative and interdisciplinary research focused on mobility in aging, where mobility may include physiological, social, and financial mobility, as well as mobility within community or health systems. These grants are intended to stimulate new collaborations and allow researchers to collect preliminary data, conduct feasibility or pilot studies, or scaling of interventions. The ultimate goal of this funding is to support future proposals for full-scale studies. Each Faculty, through the Associate Dean (Research), is asked to nominate one proposal to be funded by MIRA. Submissions should include researchers from at least three different McMaster Faculties as meaningful contributors to the project. These grants require matching funds of at least $5000 (up to $2500 may be in-kind contributions) from alternate sources to support the project. For more details, click here; Download the application form here.

## Canadian Longitudinal Study on Aging: Call for Proposals

**2019 application deadlines: June 3, and September 23**

**Funding available: MIRA can support access fees ($3,000) for up to 10 CLSA data applications**

MIRA members are eligible for support in accessing CLSA data, a national database tracking 50,000 Canadians aged 45 to 85 over a period of 20 years. Data access applications are accepted three times per year. Researchers should notify Audrey Patocs by emailing her at patocsae@mcmaster.ca prior to applying for CLSA data access to be considered for MIRA funding. MIRA funds will be allocated only to projects that do not have any other funding for this purpose. More information

## MIRA/LCMA Matching Funding for External, Competitive Funding Calls

**Deadline: Rolling**

**Funding available: Matching funds up to $100,000**

In order to improve the positioning of McMaster’s researchers in external funding competitions, MIRA and the Labarge Centre for Mobility in Aging have allocated funding that may be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component. For more details, click here and here.

## Research Project Management Course at UofT

Good project management is vital to the success of major research projects. UofT has developed a course specifically tailored for the project management of research projects. The course has been adapted for research project management through the collaboration of an Advisory Group of faculty and staff, the School of Continuing Studies, staff from the Division of the Vice-President, Research & Innovation, and the instructor, Dr. Alison Paprica. Dr. Paprica (Assistant Professor [status] at the U of T Institute of Health Policy, Management & Evaluation), was previously the Director responsible for up to $60 million/year of government research funding and has also led numerous large-scale R&D projects in the private, public and not-for-profit sectors.

The course is designed for faculty researchers, staff scientists, post-doctoral fellows, research coordinators and those interested in a path to management and research leadership. This is the second year the course is being offered. Last year, given demand for the fall course, we mounted an additional section for the winter.

Information and registration can be found at 3382 Project Management for Research.

## Invitation for feedback: Prioritizing Future Challenges for Canada

Canada’s three research granting agencies, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the Social Sciences and Humanities Research Council of Canada (CIHR, NSERC, SSHRC), and the Canada Foundation for Innovation, are seeking your expertise to help prioritize which future challenges identified through a
recent horizon scan are considered most important for Canada.

Outcomes from this consultation may also be leveraged to support the priorities of the Canada Research Coordinating Committee (CRCC), notably to advance efforts in identifying key emerging research areas. Stakeholders from all four agencies are invited to participate in this consultation. Information on the CRCC’s priorities is available on the CRCC’s website. Building upon the success of SSHRC’s 2014 Imagining Canada’s Future initiative, the granting agencies partnered with Policy Horizons Canada, a federal centre of foresight expertise, to undertake a horizon scan as a first step in identifying future challenges for Canada over the next 10 to 15 years.

Policy Horizons Canada drew on sources from across digital media, academic studies, and foresight projects to identify and analyze change data for its global scan. They also conducted a literature review of over 600 early change indicators, and examined additional materials produced by Policy Horizons Canada, government departments and agencies, and other organizations around the world. These approaches were complemented by an online questionnaire engaging various key networks and foresight communities from more than 60 countries.

The scan has identified 16 future challenges with the potential to shape society in profound ways, and which are all multi-disciplinary and require broad collaboration to address. The granting agencies ask that you select one top challenge and explore its possible impacts through a brief survey. For the challenge you select, you will be asked a series of questions. You will have the option of repeating the exercise for a challenge you deem of next-most importance. The granting agencies are inviting input from a variety of individuals across the academic, private, public and not-for-profit sectors, in Canada and internationally. Beyond the 16 challenges identified in the horizon scan, you have the opportunity to identify additional challenges deemed critical to Canada’s future.

By taking part in their brief prioritization exercise, using the Futurescaper crowdsourcing tool, you will help to identify which challenges to consider for possible future programming and/or corporate activities. Once you have reviewed the 16 future challenges, the exercise will take you about 10 to 15 minutes to complete. To begin, please follow this link: FUTURE CHALLENGES PRIORITIZATION

Results of this foresight exercise will be available by spring 2019. Responses are anonymous, and results will be aggregated to ensure anonymity.

Associated Links:
- Imagining Canada’s Future initiative
- Policy Horizons Canada
- Canada Research Coordinating Committee
- Social Sciences and Humanities Research Council of Canada
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
- Canada Foundation for Innovation

Compilation of GDPR Guidances Now Available
The Office for Human Research Protections has developed a new resource for IRBs, researchers, and sponsors that are involved in human subjects research in Europe. Titled Compilation of European GDPR Guidances, the document lists the data protection authorities of all European countries that fall under the new E.U. General Data Protection Directive (GDPR). For each country, the compilation also provides the links to any general GDPR guidances, as well as specific guidances on the topics of Research, Legal Basis, Consent, and International Data Transfer.

The new Compilation is available here:
https://www.hhs.gov/ohrp/international/index.html
**Health Research Grant Competitions**

*Programs administered by Health Research Services, unless otherwise indicated. Email: hsresadm@mcmaster.ca*

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR – Team Grant: Transnational Cardiovascular Research Projects</td>
<td>April 15</td>
<td>April 29</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: Indigenous Component of Healthy Life Trajectories (I-HeLTI)</td>
<td>April 17</td>
<td>May 1</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> CIHR – ME (Myalgic Encephalomyelitis) Network Catalyst Grant</td>
<td>April 25</td>
<td>May 9</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: 9th Joint Programming Initiative on Antimicrobial Resistance (JPIMR)</td>
<td>June 3</td>
<td>June 17</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: CIHR Summer Institute on Equitable AI for Public Health</td>
<td>June 4</td>
<td>June 18</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: Canadian Cancer Society Cancer Survivorship</td>
<td>May 29</td>
<td>Aug 27</td>
<td>Sept 10</td>
</tr>
<tr>
<td>CIHR – Team Grant: Cannabis Research in Priority Areas</td>
<td>May 15</td>
<td>Sept 24</td>
<td>Oct 8</td>
</tr>
<tr>
<td>CIHR – Team Grant: Next Generation Networks for Neuroscience (NeuroNEX)</td>
<td>June 14</td>
<td>Nov 29</td>
<td>Dec 13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (Non-CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simons Foundation Autism Research Initiative (SFARI): Summer 2019 Pilot Award</td>
<td>April 4</td>
<td>April 18</td>
<td></td>
</tr>
<tr>
<td>SickKids Foundation: New Investigator Grants</td>
<td>April 8</td>
<td>April 22</td>
<td></td>
</tr>
<tr>
<td>Canadian Research Society: Next Generation of Scientists</td>
<td>April 12</td>
<td>April 26</td>
<td></td>
</tr>
<tr>
<td><strong>2020 Killam Research Fellowships Competition</strong></td>
<td>May 1</td>
<td>May 15</td>
<td></td>
</tr>
<tr>
<td>Active &amp; Assisted Living Programme: Sustainable Smart Solutions for Ageing Well Call for Proposals</td>
<td>May 10</td>
<td>May 24</td>
<td></td>
</tr>
<tr>
<td>Asthma Canada-CAAIF Goran-Enhorning Graduate Student Research Award: Early-onset Asthma Research Award</td>
<td>May 17</td>
<td>May 31</td>
<td></td>
</tr>
<tr>
<td>Asthma Canada-CAAIF Bastable-Potts Graduate Student Research Award: Late-onset Asthma Research Award</td>
<td>May 17</td>
<td>May 31</td>
<td></td>
</tr>
<tr>
<td>Child Health Foundation: Innovative Small Grants Program</td>
<td>May 17</td>
<td>May 31</td>
<td></td>
</tr>
<tr>
<td>Pharmacotherapies for Alcohol and Substance Abuse Consortium (PASA): Grant Program – (RFA) #4a</td>
<td>April 22</td>
<td>May 20</td>
<td>June 3</td>
</tr>
<tr>
<td>Arthritis Society: Stars Career Development Award</td>
<td>May 22</td>
<td>June 12</td>
<td>June 26</td>
</tr>
<tr>
<td>Weston Brain Institute Rapid Response Parkinson’s &amp; Related Diseases</td>
<td>May 15</td>
<td>July 2</td>
<td>July 16</td>
</tr>
<tr>
<td>Weston Brain Institute Transformational Research Parkinson’s &amp; Related Diseases</td>
<td>May 15</td>
<td>July 2</td>
<td>July 16</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation Grants: Therapeutic Pipeline Program</td>
<td>April 19</td>
<td>July 5</td>
<td>July 19</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation Grants: Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein</td>
<td>April 19</td>
<td>July 5</td>
<td>July 19</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation Grants: Biology of Astrocytes in Parkinson’s Disease</td>
<td>April 19</td>
<td>July 5</td>
<td>July 19</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation Grants: Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy</td>
<td>April 19</td>
<td>July 5</td>
<td>July 19</td>
</tr>
<tr>
<td>Pharmacotherapies for Alcohol and Substance Abuse Consortium (PASA): Grant Program – (RFA) #4b</td>
<td>May 13</td>
<td>July 8</td>
<td>July 22</td>
</tr>
<tr>
<td>Funding Opportunity (DoD) (eBRAP account required – must be validated by McMaster prior to any submission)</td>
<td>LOI Deadline</td>
<td>Internal HRS Deadline</td>
<td>Sponsor Deadline</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Exploration Hypothesis Development Award</td>
<td>April 18</td>
<td>April 25</td>
<td>May 9</td>
</tr>
<tr>
<td>Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Idea Development Award</td>
<td>April 18</td>
<td>April 25</td>
<td>May 9</td>
</tr>
<tr>
<td>Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Clinical Translational Research Award</td>
<td>April 18</td>
<td>April 25</td>
<td>May 9</td>
</tr>
<tr>
<td>Program</td>
<td>Award Type</td>
<td>Start Date</td>
<td>End Dates</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Department of Defense (DoD) Neurofibromatosis Research Program (NFRP):</td>
<td>Clinical Trial Award</td>
<td>May 23</td>
<td>June 6</td>
</tr>
<tr>
<td>Department of Defense (DoD) Neurofibromatosis Research Program (NFRP):</td>
<td>Exploration – Hypothesis Development Award</td>
<td>May 23</td>
<td>June 6</td>
</tr>
<tr>
<td>Department of Defense (DoD) Neurofibromatosis Research Program (NFRP):</td>
<td>Investigator-Initiated Research Award</td>
<td>May 23</td>
<td>June 6</td>
</tr>
<tr>
<td>Department of Defense (DoD) Neurofibromatosis Research Program (NFRP):</td>
<td>New Investigator Award</td>
<td>May 23</td>
<td>June 6</td>
</tr>
<tr>
<td>Department of Defense (DoD) Parkinson’s Research Program (PRP):</td>
<td>Early Investigator Research Award</td>
<td>July 9</td>
<td>July 24</td>
</tr>
<tr>
<td>Department of Defense (DoD) Parkinson’s Research Program (PRP):</td>
<td>Investigator-Initiated Research Award</td>
<td>July 9</td>
<td>July 24</td>
</tr>
<tr>
<td>Department of Defense (DoD) Ovarian Cancer Research Program (OCRP):</td>
<td>Pilot Award</td>
<td>April 23</td>
<td>July 24</td>
</tr>
<tr>
<td>Department of Defense (DoD) Ovarian Cancer Research Program (OCRP):</td>
<td>Investigator-Initiated Research Award</td>
<td>April 23</td>
<td>July 24</td>
</tr>
<tr>
<td>Department of Defense (DoD) Ovarian Cancer Research Program (OCRP):</td>
<td>Ovarian Cancer Academy Award - Early-Career Investigator</td>
<td>April 30</td>
<td>July 31</td>
</tr>
<tr>
<td>Department of Defense (DoD) Ovarian Cancer Research Program (OCRP):</td>
<td>Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award</td>
<td>April 30</td>
<td>July 31</td>
</tr>
<tr>
<td>Department of Defense (DoD) Ovarian Cancer Research Program (OCRP):</td>
<td>Clinical Development Award</td>
<td>April 30</td>
<td>July 31</td>
</tr>
<tr>
<td>Department of Defense (DoD) Autism Research Program (ARP):</td>
<td>Clinical Trial Award</td>
<td>May 1</td>
<td>Aug 8</td>
</tr>
<tr>
<td>Department of Defense (DoD) Autism Research Program (ARP):</td>
<td>Idea Development Award</td>
<td>May 1</td>
<td>Aug 8</td>
</tr>
<tr>
<td>Department of Defense (DoD) Autism Research Program (ARP):</td>
<td>Clinical Translational Research Award</td>
<td>May 1</td>
<td>Aug 8</td>
</tr>
<tr>
<td>Department of Defense (DoD) Lung Cancer Research Program (LCRP):</td>
<td>Career Development Award</td>
<td>Aug 1</td>
<td>Aug 21</td>
</tr>
<tr>
<td>Department of Defense (DoD) Lung Cancer Research Program (LCRP):</td>
<td>Idea Development Award</td>
<td>May 15</td>
<td>Aug 21</td>
</tr>
<tr>
<td>Department of Defense (DoD) Lung Cancer Research Program (LCRP):</td>
<td>Investigator Initiated Translational Research Award</td>
<td>May 15</td>
<td>Aug 21</td>
</tr>
<tr>
<td>Department of Defense (DoD) Lung Cancer Research Program (LCRP):</td>
<td>Translational Research Partnership Award</td>
<td>May 15</td>
<td>Aug 21</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense (DoD) Tick-Borne Disease Research Program</td>
<td>Career Development Award</td>
<td>May 22</td>
<td>Aug 22</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense (DoD) Tick-Borne Disease Research Program</td>
<td>Idea Award</td>
<td>May 22</td>
<td>Aug 22</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense (DoD) Tick-Borne Disease Research Program</td>
<td>Investigator-Initiated Research Award</td>
<td>May 22</td>
<td>Aug 22</td>
</tr>
<tr>
<td>Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Career Development Award</td>
<td>May 21</td>
<td>Aug 28</td>
<td>Sept 11</td>
</tr>
<tr>
<td>Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Horizon Award</td>
<td>Aug 21</td>
<td>Aug 28</td>
<td>Sept 11</td>
</tr>
</tbody>
</table>
**CIHR – Team Grant: Transnational Cardiovascular Research Projects**

The ERA-CVD JTC2019: Transnational Cardiovascular Research Projects driven by Early Career Scientists is expected to:

- foster transnational cooperation of European countries and beyond, and to coordinate research efforts and funding programs of the ERA-CVD partner countries with Canada
- promote co-operation and interchange between Early Career Scientists and thus enable international collaboration and new consortia establishment in cardiovascular research,
- enable capacity building and empowering of Early Career Scientists by providing opportunity to independently develop and perform highly innovative research projects,
- add value in funding the collaboration over individual projects by sharing of resources (e.g., models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.

**Funding Details:** CIHR-ICR is partnering with other ERA-CVD partners to provide approximately EUR 10 million for JTC2019. The total amount available for Canadian applications is CAD 600,000, which is enough to fund approximately two (2) grants. This amount may increase if additional funding partners participate. The maximum amount available per grant to Canadian participants in transnational consortia is CAD 100,000 per year for up to three (3) years for a total of CAD 300,000, per grant.

**Additional Details**

Internal HRS Deadline: **April 15, 2019**
Sponsor Deadline: **April 29, 2019**

**CIHR – Team Grant: Indigenous Component of Healthy Life Trajectories (I-HeLTI)**

Non-communicable diseases (NCDs) are responsible for more than 60% of deaths globally, and 80% of these NCD-associated deaths occur in countries that have experienced rapid changes in population demographics (2–4 generations) and environments, including urbanisation, lifestyle changes and changes in diet. To address these issues, CIHR developed the Healthy Life Trajectories Initiative (HeLTI), which follows a Developmental Origins of Health and Disease (DOHaD) approach, by exploring how the interaction of environmental factors with genes prior to and during conception, pregnancy, infancy and early childhood impacts an individual’s health and the development of NCDs in later life. CIHR is currently funding an International component of HeLTI, through a partnership among research teams, the World Health Organization, and funding agencies based in Canada, South Africa, China and India. These countries have experienced rapid changes in population demographics and environments, and have a high incidence of NCDs.

NCDs, including diabetes, cardiovascular diseases, and respiratory diseases, are also a priority issue for Indigenous Peoples (First Nations, Inuit and Métis) in Canada. CIHR has therefore launched the Indigenous component of HeLTI (I-HeLTI) to address similar issues faced by and specific to Indigenous Peoples in Canada. I-HeLTI will take a DOHaD approach, supporting the development, implementation, testing and evaluation of Indigenous-focused early interventions (preconception, pregnancy, infancy and early childhood) designed to improve health outcomes in later life for Indigenous boys, girls, women, men, gender-diverse and Two-Spirit individuals in Canada.

Development Grants have been funded to bring interested Indigenous communities together with self-identified relevant organizations to build community participation in I-HeLTI and to establish needed expertise to support Indigenous-driven health research. Recipients of these Development Grants participated in a Strengthening Workshop that addressed community readiness, priorities, research capacity, data capacity considerations, sex and gender considerations and governance, as well as building relationships with researchers.

This funding opportunity will fund four (4) I-HeLTI research teams that will build the infrastructure and capacity that is needed to conduct an Indigenous-driven I-HeLTI DOHaD Intervention Cohort Research Study. This funding opportunity is not restricted only to those who received a development grant. I-HeLTI will operate according to Indigenous self-governance and self-determination, recognizing the need to respect how Indigenous Peoples must be involved in health research.

A subsequent funding opportunity for one (1) Indigenous-driven I-HeLTI DOHaD Intervention Cohort will coincide with the renewal date of the team grant funding. It is expected that the four funded teams will collaborate to respond to the intervention cohort

---

<table>
<thead>
<tr>
<th>Program Name</th>
<th>Deadline Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP):</td>
<td>May 22    Aug 28   Sept 11</td>
</tr>
<tr>
<td>Idea Award with Special Focus</td>
<td></td>
</tr>
<tr>
<td>Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP):</td>
<td>May 22    Aug 28   Sept 11</td>
</tr>
<tr>
<td>Impact Award</td>
<td></td>
</tr>
<tr>
<td>Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP):</td>
<td>May 22    Aug 28   Sept 11</td>
</tr>
<tr>
<td>Translational Team Science Award</td>
<td></td>
</tr>
</tbody>
</table>
funding opportunity and establish one Indigenous-driven I-HeLTI DOHaD Intervention Cohort. As such, the funded research teams will collaborate to develop the partnerships, and leverage the necessary expertise and resources to establish an Indigenous-driven I-HeLTI DOHaD Intervention Cohort. This will include working together to define roles and responsibilities around research governance, and research data management.

As part of this, the funded teams will be provided with the common dataset variables that are being collected by the International component of HeLTI in order to determine which of the variables are culturally appropriate and feasible for use in I-HeLTI. They will also evaluate the data management processes established by the International cohorts for utility in I-HeLTI. Funded teams will then develop data management processes including how data and biosamples will be collected, documented and stored during the lifecycle of the project in a manner that will optimize the opportunity to share, link, integrate and harmonize data, if and when Indigenous Peoples make the decision to do so.

This funding opportunity is to support research over two (2) fiscal years (2019-20 to 2020-21) with the possibility of renewals for a total of eight years of support up to 2026-27. In order to enable the development of infrastructure and capacity by each of the teams in preparation for joining the Indigenous-driven I-HeLTI DOHaD Intervention Cohort, in the first two years (fiscal years 2019-20 to 2020-21), the teams will receive infrastructure funding to support capacity building and infrastructure in addition to baseline funding. Upon renewal, the baseline funding will then continue for the remaining term (up to fiscal year 2026-27) of the team grants to provide local funding to each of the teams to support their roles within the overall I-HeLTI DOHaD Intervention Cohort collaboration.

I-HeLTI team grants will sustain the I-HeLTI investment through long-term Indigenous community engagement and institutional commitments.

Research Areas
This funding opportunity will support teams to build infrastructure and capacity along the continuum of care and prevention from preconception to pregnancy, infancy and early childhood, with a life trajectory perspective relevant to the following research areas:

- A DOHaD / life trajectory approach;
- A focus on the prevention of NCDs; and
- An intervention cohort design.

Interventions must target evidence-based, modifiable risk factors for one or more NCDs. Interventions can be natural experiments (e.g., policy, programs, or other interventions not under the control of a researcher), or newly implemented or adapted interventions delivered by the researcher team or others.

For this I-HeLTI funding opportunity, the objectives will need to be addressed within an Indigenous health research context. That is, the approach to the funding opportunity objectives will need to be conducted by, grounded in, or engaged with First Nations, Inuit or Métis communities, societies or individuals and their wisdom, cultures, experiences or knowledge systems, as expressed in their dynamic forms, past and present.

Funding Details: The total amount available for this funding opportunity is $4,050,000, enough to fund four (4) grants over two (2) years. The maximum amount per grant for this funding opportunity is $1,012,500, with the possibility of renewals.

- Of the $1,012,500 per grant:
  - $325,000 is available for the team activities (baseline funding – $125,000 in year 1 and $200,000 in year 2)
  - $687,500 is available per grant to support infrastructure, capacity building and partnerships. ($325,000 in year 1 and $362,500 in year 2).
- There is the possibility of renewals for an additional total amount of $4,800,000. An additional $1,200,000 per grant ($200,000 per year for up to six [6] years) will be available for renewals if successful in joining the one (1) funded Indigenous-driven I-HeLTI DOHaD Intervention Cohort.

Additional Details
Internal HRS Deadline: April 17, 2019
Sponsor Deadline: May 1, 2019

**CIHR – ME (Myalgic Encephalomyelitis) Network Catalyst Grant**

Myalgic Encephalomyelitis (ME), also known as Chronic Fatigue Syndrome (CFS), is a poorly understood, complex and debilitating disorder that severely impacts the lives of an estimated 800,000 to 2.5 million Americans, and approximately 560,000 Canadians. The underlying etiology and pathophysiology of ME are unknown and there is no diagnostic test for the disease. Consequently, there is currently no gold standard for case definition of ME.
The CHR Institute of Musculoskeletal Health and Arthritis (IMHA), in partnership with the Institute of Circulatory and Respiratory Health (ICRH) and the Institute of Infection and Immunity (III), and with the collaboration of the Institute of Neuroscience, Mental Health and Addiction (INMHA), will support a Network that will generate new knowledge to improve diagnosis and treatment of ME disease in Canada. The network will foster innovative research, build capacity, and be both a catalyst and a forum for discussing ideas, sharing best practices and consulting on challenges. Research will include efforts to define the cause(s) of the condition and test new and existing treatments for ME.

The Network is expected to be:

- national in scope — incorporating multiple research groups and researchers
- collaborative — partnering with stakeholders (not-for-profit organizations, associations, industry, provinces, etc.) and facilitating interactions between stakeholders and the scientific community (clinicians, decision makers, industry, patients, and other knowledge-users outside of the academic community)
- inclusive, multidisciplinary and multi-themed
- committed to scientific excellence

The successful Network is encouraged to coordinate with existing initiatives in the field, to forge links with the wider community (including practitioners, policy makers and service users) and include additional partners, such as commercial or industrial representatives. More specifically, the successful Network is encouraged to coordinate with the three US-based Collaborative Research Centers (CRC) and the Data Management Coordinating Center (DMCC) funded in September 2017 by the National Institutes of Health.

In addition to funding a new research network in ME, supplementary funding may be awarded to the network for studying vascular instability and/or sleep disturbances experienced by people who live with ME (see “How to Apply” for details).

**Funding Details**: The total amount available for this funding opportunity is $1,775,000. Of this:

- $1,400,000 is available from IMHA and III for a new research network in ME, enough to fund one (1) network grant. This amount may increase if additional funding partners participate. The maximum amount for the grant is $280,000 per year for up to five (5) years.
- $375,000 is available as supplementary funding from ICRH for the inclusion of a project addressing vascular instability and/or sleep disturbances experienced by people with ME. The maximum amount of supplementary funding is $75,000 per year for up to five (5) years.

**Additional Details**

**Internal HRS Deadline**: April 17, 2019  
**Sponsor Deadline**: May 1, 2019

**CIHR – Operating Grant: 9th Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)**

The funding opportunity is expected to:

Contribute to the urgent need to curb the burden associated with the most prioritized infections in different geographical settings through international collaborations, combining complementary and synergistic research strengths and a One Health perspective.

This topic area is also suitable to reinforce collaborations involving industry and social sciences. Regional LMIC-led collaborations are welcomed. The results of the funded projects should contribute to improved understanding, monitoring and detection of AMR where efforts to curb AMR will have a global impact.

For more information, please consult the JPIAMR website.

This funding opportunity will support projects relevant to the following research areas:

- Establish the validity of new or improved diagnostic tools, technologies and methods.
- Evaluate how new or improved diagnostics can promote more prudent use of antibiotics (e.g., narrow spectrum antibiotics) in human and veterinary use.
- Rapid diagnostics (essential for optimal antimicrobial selection) and point-of-care techniques, to improve personalized or individual therapies.
- Development of new, or more efficient use and accessibility of already existing, tools, technologies and/or methods to detect AMR in multiple reservoirs, for example human, animal and environmental samples, for example:
  - Improvement and standardisation of bioinformatics pipelines, quality control, and/or modelling and analysis tools for WGS data and metadata.
  - Methods and tools for defining baseline data with regards to the natural variability of resistance genes, mobile genetic elements and/or mobilization/transfer frequencies in different types of environments and/or expanding quantitative microbial risk assessment to encompass also, e.g., ecology and evolutionary aspects of AMR.
➢ Implementation strategies and/or improvement or further development of existing tools that distinguish between viral, susceptible bacterial and antimicrobial-resistant bacterial infections.

Projects are encouraged to consider the global use of the tools, technologies and methods, including use in LMIC settings (e.g. lack of laboratory facilities, affordable diagnostic tests, unreliable or unavailable electricity supplies or points-of-care-tests).

➢ Funding Details: The total amount available for this funding opportunity is CAD 1.8 million, enough to fund approximately 4 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is based upon the nature of Canadian participation on the funded application as follows:
  ➢ Canadian investigator–led Consortium (Coordinator): The maximum per grant is up to CAD 175,000 per year for up to 3 years, for a total of CAD 525,000 per grant.
  ➢ Canadian investigator participation (Partner): The maximum per grant is up to CAD 125,000 per year for up to 3 years, for a total of CAD 375,000.

➢ Approved grants may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities.

Additional Details

Internal HRS Deadline: June 3, 2019
Sponsor Deadline: June 17, 2019

CIHR – Operating Grant: CIHR Summer Institute on Equitable AI for Public Health

The main objectives of the CIHR Summer Institute on Equitable AI for Public Health funding opportunity, led by the host institution(s) are to:

➢ Equip doctoral and post-doctoral trainees and early career researchers from primarily public health and, secondarily, computational sciences backgrounds with the technical skills to use AI approaches and methods to tackle key public health challenges;

➢ Prepare participants to address the equity implications of different AI approaches, including identifying strategies to prevent and mitigate potential inequities that could result when using AI approaches in public health research and practice, and opportunities for leveraging AI to advance health equity;

➢ Facilitate a high-quality, interdisciplinary learning environment that offers participants from across Canada the opportunity to interact with others from a diverse range of backgrounds and disciplines within public health and computational sciences, as well as Canadian and international leaders and implementers working in AI and public health; and

➢ Catalyze the development of open-access training content and materials focused on using AI approaches in public health research that can be adapted and integrated into curricula for trainees at schools of public health and related disciplines, and among staff at public health agencies across Canada.

➢ Funding Details: $525,000 over five (5) years, enough to fund one grant. This amount may increase if additional funding partners participate.

Additional Details

Internal HRS Deadline: June 4, 2019
Sponsor Deadline: June 18, 2019

CIHR – Team Grant: Canadian Cancer Society Cancer Survivorship

The goal of the CCS/CIHR Cancer Survivorship Team Grant program is to improve the health outcomes for cancer survivors of all ages (pediatric, adolescent, young adult and adult) from the time of their cancer diagnosis until the time of their death or entry into palliative care. This program is not intended to focus on improving end-of-life care.

The intent of this funding opportunity is to support new intervention research designed to mitigate the challenges experienced along the survivorship journey, as well as the evaluation and validation of existing interventions to assess their potential for implementation as best practices.

The program goal will be achieved through the support of a network of multidisciplinary teams, each led by a nominated Principal Investigator and at least 2 co-Principal and/or co- Applicants, one of whom must be within their first five years as an independent researcher, drawn from at least 3 different regions of Canada (Atlantic Provinces, Central Canada, Prairie Provinces, West Coast, Northern Territories).

Collectively, successful teams will be expected to generate relevant new knowledge and to develop and evaluate practical strategies and interventions, in real world settings, that will prevent or diminish the adverse sequelae of a cancer diagnosis and have a positive impact on subsequent health outcomes for cancer survivors.
Collectively, successful teams will be expected to generate relevant new knowledge and to develop and evaluate practical strategies and interventions, in real world settings, that will prevent or diminish the adverse sequelae of a cancer diagnosis and have a positive impact on subsequent health outcomes for cancer survivors.

In addition, each team will be required to develop a well-designed plan for integration within their team of:

- Implementation science approaches aimed at facilitating the development of strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and/or sustainability of evidence-based interventions. Strategies designed to integrate evidence-based interventions into specific settings are strongly encouraged.
- A research model that embodies the values of community-based participatory research (CBPR), in which survivors and their family/friend caregivers are engaged throughout the entire research process from the development of the initial research questions to the dissemination and application of research findings.
- Each team should include (have a balance of) investigators across the continuum of a research career (early, mid and late), (Assistant, Associate, Full) professorship, and diversity, with a built-in plan for mentorship and sustainability.

The program goal will be achieved through regular networking events/activities designed to support and augment individual teams’ capacities to catalyze survivor/caregiver engagement and knowledge mobilization.

**Funding Details:** Teams may request up to $500,000 per year for a maximum of $2,500,000 over a five-year period. Grants will be non-renewable. As the total budget for this competition is $10 million, it is anticipated that at least 4 teams will be funded in this competition. The engagement of additional partners may increase this number.

Funding will be provided to support the direct costs of research, including supplies, salaries, and equipment associated with the proposed work. Equipment requests cannot exceed 10% of the requested budget. Indirect costs are not eligible. *Note that funds should be set aside in the budget to facilitate travel of teams for networking purposes annually.

**Additional Details**

**LOI Deadline:** May 29, 2019

**Internal HRS Deadline:** August 27, 2019

**Sponsor Deadline:** September 10, 2019

**CIHR – Team Grant: Cannabis Research in Priority Areas**

On October 17, 2018, the Cannabis Act came into force in Canada, legalizing non-medical cannabis products including fresh and dried cannabis, and cannabis oils. Other products, such as edible products and concentrates, are expected to be legal for sale in Fall 2019. There remain many unknowns about the use of cannabis, its health and safety effects and the behavioural, social, cultural, ethical and economic implications of legalization both nationally and across jurisdictions. A number of reports have highlighted the need for enhanced research evidence to inform policy, therapeutic practice, harm reduction, and prevention efforts.

In December 2017, CIHR invested $1.4 million to support 14 projects to catalyze future research related to the health impacts of cannabis legalization. That catalyst grant funding opportunity had a specific focus on population health intervention research related to the legalization and regulation of non-medical cannabis in Canada. Further, in July 2018, CIHR and partners invested $3 million to support an additional 24 projects designed to address urgent priority areas identified through a research priorities workshop held in September 2017. Identified research areas included both the potential therapeutic benefit for specific indications and the potential risks/harms of cannabis use in different populations. However, there still remain many unknowns about the health and safety effects of cannabis, as well as the behavioural, social, ethical and economic implications of legalization.

To address these issues, CIHR and partner agencies have developed an Integrated Cannabis Research Strategy (ICRS). The overarching vision of ICRS is to provide a well-coordinated series of activities to position Canada as a leader in developing the research capacity and amassing the research evidence needed on the effects of cannabis. This includes validating the potential therapeutic benefits of cannabis, as well as understanding risks and harms, and supporting policy and regulatory models for studying cannabis use (including development of common data standards). This Team Grant funding opportunity represents the first targeted funding opportunity launched under ICRS, with additional opportunities planned in the coming years.

The purpose of the current Team Grant is to explore in more detail the potential therapeutic benefits and harms associated with cannabis use in a number of targeted areas identified through previous consultations. In particular, these Team Grants will address stakeholder priorities by supporting specific defined priority areas in targeted pools, to strengthen the evidence base and to build cannabis-related research capacity.

To ensure that applications address the ethical, environmental, economic, legal, social and cultural aspects associated with cannabis research, applications should demonstrate relevant interdisciplinary expertise encompassing research domains from natural sciences
and engineering, health sciences, and social sciences and humanities, as appropriate, in their applications. Applicants must propose a knowledge translation plan and demonstrate how they will incorporate open science practices in their research program.

Applicants must integrate sex as a biological variable and gender as a social determinant of health, as appropriate, into their research to promote rigorous science that has the potential to expand our understanding of health determinants for all people. As such, applicants are required to indicate how they will account for sex (biological factor) and gender (socio-cultural factor) in the research design, methods, analysis and interpretation, and dissemination of findings. For more information and resources, please see the Sex, Gender and Health Research page on the CIHR website.

**Funding Details:** The total amount available for this funding opportunity is $16.5 million, enough to fund approximately 11 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $300,000 per year for up to 5 years, for a total of $1.5 million per grant.

Of this $16.5 million:

- $1.5 million is available to fund an application relevant to the Cancer Pool (sponsored by the Canadian Cancer Society, ICR, and INMHA).
- $1.5 million is available to fund an application relevant to the Cardio-Respiratory/Sleep Pool (sponsored by ICRH).
- $1.5 million is available to fund an application relevant to the Neurodevelopment Pool (sponsored by IHDCYH).
- $1.5 million is available to fund an application relevant to the Indigenous Peoples' Health Pool (sponsored by IIPH and INMHA).
- $1.5 million is available to fund an application relevant to the IMHA Pain Pool (sponsored by IMHA).
- $1.5 million is available to fund an application relevant to the Arthritis Pain Pool (sponsored by the Arthritis Society and INMHA).
- $4.5 million is available to fund applications relevant to the Mental Health Pool (sponsored by INMHA and MHCC).
- $1.5 million is available to fund an application relevant to the MS Pool (sponsored by the MS Society of Canada and INMHA).
- $1.5 million is available to fund an application in any of the Research Areas pools in overall rank order of application (sponsored by INMHA).
- If any additional unrestricted funds are secured, they will be applied to fund applications in any of the indicated Research Areas pools in overall rank order of application.

**Additional Details**

**LOI Deadline:** May 15, 2019

**Internal HRS Deadline:** September 24, 2019

**Sponsor Deadline:** October 8, 2019

**CIHR – Team Grant: Next Generation Networks for Neuroscience (NeuroNEX)**

CIHR and FRQ have decided to support Canadian investigators on a large-scale, interdisciplinary, international brain research initiative. Understanding how behavior emerges from the dynamic patterns of electrical and chemical activity of brain circuits is universally recognized as one of the great, unsolved mysteries of science. Advances in recent decades have elucidated how individual elements of the nervous system and brain relate to specific behaviors and cognitive processes. However, there remains much to discover to attain a comprehensive understanding of how the healthy brain functions, specifically, the general principles underlying how cognition and behavior relate to the brain’s structural organization and dynamic activities, how the brain interacts with its environment, and how brains maintain their functionality over time.

As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative in the United States, the US National Science Foundation (NSF) has developed the Next Generation Networks for Neuroscience (NeuroNex). The objective of the NeuroNex program is the establishment of distributed, international research networks that build on existing global investments in neurotechnologies to address overarching questions in neuroscience. The creation of such global research networks of excellence will foster international cooperation by seeding close interactions between a wide array of organizations across the world, as well as creating links and articulating alliances between multiple recently launched international brain projects. Canadian researchers are well placed to provide a leadership role within NeuroNex networks.

The goal of the NeuroNex Technology-enabled, Team-based Neuroscience solicitation is to support collaborative networks comprised of international teams of disciplinarily-diverse researchers working on a common foundational question in neuroscience. Each network will be organized around a central theme identified by the participants. Individual networks will be composed of 2 to 4 interdisciplinary research groups (IRGs), each consisting of about 3 to 6 investigators. Each IRG will have a defined intellectual role that fits within the overall research goal of the network. It is envisaged that the composition of each IRG may cut across organizations and countries, as appropriate. Through this funding opportunity, CIHR and FRQ will support Canadian investigators on NeuroNex IRGs.
**Funding Details**: The maximum amount per grant is $250,000 per year for up to 5 years for a total of $1,250,000 per grant.

**Additional Details**

**Pre-Proposal Deadline**: June 14, 2019  
**Internal HRS Deadline**: November 29, 2019  
**Sponsor Deadline**: December 13, 2019

---

**Simons Foundation Autism Research Initiative (SFARI): Summer 2019 Pilot Award**

The goal of the Pilot Award is to provide early support for exploratory ideas, particularly those with novel hypotheses. Appropriate projects for this mechanism include those considered higher risk but with the potential for transformative results. To get a better understanding of SFARI’s different RFAs and whether the Pilot Award may be the best mechanism to support your project, please read our blog post “SFARI RFA reboot: Why, what and how?”

In particular, we encourage applications that propose research to link genetic or other ASD risk factors to molecular, cellular, circuit or behavioral mechanisms of ASD. Please read more about SFARI’s scientific perspectives here. We also strongly advise applicants to familiarize themselves with the current projects and other resources that SFARI supports and to think about how their proposals might complement existing efforts.

**Funding Details**: A maximum $300,000 over a maximum 2 years.

**Additional Details**

**Internal HRS Deadline**: April 4, 2019  
**Sponsor Deadline**: April 18, 2019

---

**SickKids Foundation: New Investigator Grants**

The objective is to provide early career development support to new child health investigators who successfully lead, participate in, and translate outstanding child health research that responds to children’s health challenges and needs. Research in the biomedical, clinical, health systems and services, population and public health sectors, are eligible.

The Principal Investigator (PI) must hold a doctoral degree (Ph.D.) or equivalent medical/health care degree, and have had formal research training. The PI must be within five years of their first academic appointment, and has not been awarded combined Operating Grant funding of $500,000 or more.

**Funding Details**: A maximum $100,000 per year for a maximum 3 years.

**Additional Details**

**Internal HRS Deadline**: April 8, 2019  
**Sponsor Deadline**: April 22, 2019

---

**Canadian Research Society: Next Generation of Scientists**

Scholarships for the Next Generation of Scientists is a Cancer Research Society funding program with the goal of supporting the future generation of Canadian researchers. The award consists of two part covering a period of three years, with no possibility for renewal.

The one-year postdoctoral salary award is for a candidate finishing his/her fellowship. The candidate must have completed at least two (2) years of postdoctoral training when he/she will accept the salary award on September 1st. There is a possibility of extending Part 1 of this award for a maximum period of six months.

The operating grant is awarded once the candidate has obtained a faculty position at a recognized Canadian institution. This grant is for a maximum of two years.

IMPORTANT: Applying for only one part of the award is prohibited.

**Funding Details**: Part 1: 1 year - $50,000. Part 2: 2 years $120,000.

**Additional Details**

**Internal HRS Deadline**: April 12, 2019  
**Sponsor Deadline**: April 26, 2019

---

**2020 Killam Research Fellowships Competition**

The Killam Research Fellowships are release time awards that provide support to scholars of exceptional ability who are engaged in research projects of broad significance and widespread interest within the disciplines of the humanities, social sciences, natural sciences, health sciences, engineering, or studies linking any of these disciplines.
**Funding Details:** Fellowships are valued at $70,000 per year for 2 years.

**Additional Details**

Internal HRS Deadline: May 1, 2019  
Sponsor Deadline: May 15, 2019

---

**Active & Assisted Living Programme: Sustainable Smart Solutions for Ageing Well Call for Proposals**

AAL Call 2019 is part of the Active & Assisted Living Programme (AAL Programme) that was approved in May 2014 by the European Parliament and the Council of the European Union. As part of the work programme, the AAL Programme intends to launch a new Call for Proposals in February 2019: “Sustainable Smart Solutions for Ageing well”.

The aim of the call is to support innovative, transnational and multi-disciplinary collaborative projects. Call 2019 is characterised by the following approach:

- The AAL Call 2019 is open to developing ICT-based solutions targeting any application area(s) within the AAL domain. The solutions need to be embedded in the strategies of the participating end-user organisations, service providers and business partners.
- The AAL Call 2019 allows for more flexibility regarding the scope, size and duration of the proposed projects (including small collaborative projects).

The AAL domains include solutions for Active Living, such as in work & training, for vitality & abilities, in leisure & culture, for information & communication, as well as for Assisted Living, such as in health & care, living & building, mobility & transport, safety & security.

**Funding Details:** The total amount available for a Canadian-based applicant for this funding opportunity is $353,000 (CAD), enough to fund approximately one (1) grant. This amount may increase if additional funding partners participate. The maximum amount per grant is $117,666 (CAD) per year for one (1) grant for a maximum of three (3) years.

**Additional Details**

Internal HRS Deadline: May 10, 2019  
Sponsor Deadline: May 24, 2019

---

**Asthma Canada-CAAIF Goran-Enhorning Graduate Student Research Award: Early-onset Asthma Research Award**

The objective of the Graduate Student Research Awards is to create value-added opportunities for the training, education, and professional development of graduate students, to ensure continued improvement of asthma treatment therapies and progress towards finding a cure for asthma.

- Research projects must contribute to an improved understanding of the mechanisms and/or treatment, management or cure of early-onset asthma (18 years and younger).
- Applicants must be full-time graduate students pursuing a PhD in Canada.
- Applicants must be Canadian citizens or permanent residents.

**Funding Details:** $20,000.

**Additional Details**

Internal HRS Deadline: May 17, 2019  
Sponsor Deadline: May 31, 2019

---

**Asthma Canada-CAAIF Bastable-Potts Graduate Student Research Award: Late-onset Asthma Research Award**

The objective of the Graduate Student Research Awards is to create value-added opportunities for the training, education, and professional development of graduate students, to ensure continued improvement of asthma treatment therapies and progress towards finding a cure for asthma.

- Research projects must contribute to an improved understanding of the mechanisms and/or treatment, management or cure of late-onset asthma (over 18 years).
- Applicants must be full-time graduate students pursuing a PhD in Canada.
- Applicants must be Canadian citizens or permanent residents.
**Funding Details:** $20,000.

**Additional Details**

**Internal HRS Deadline:** May 17, 2019  
**Sponsor Deadline:** May 31, 2019

---

**Child Health Foundation: Innovative Small Grants Program**

The objective of the Small Grants Program is to support innovative research, or innovative service projects, directed at improving the health and well-being of new-born infants during their first month of life. The CHF will consider a range of technologies and approaches including biomedical and social science projects, that show promise and may have wide-spread application. Projects must address child health issues in a developing country, or in the United States. All countries are eligible to apply.

**Funding Details:** A maximum of $5,000 for 1 year.

**Additional Details**

**Internal HRS Deadline:** May 17, 2019  
**Sponsor Deadline:** May 31, 2019

---

**Pharmacotherapies for Alcohol and Substance Abuse Consortium (PASA): Grant Program – (RFA) #4a**

The goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). The PASA Consortium accepts applications for study funding during open solicitation periods. The exact number and type of studies approved during each solicitation period will depend on the quantity and quality of applications received and amount of available funding. Notices of study application solicitation periods will be posted here on the PASA Consortium’s website, publicly advertised via professional organization e-mail list serves and conference postings, and distributed to investigators, pharmaceutical companies, and academic research institutes that are known to have potentially viable candidate compounds.

Small-cost and short-duration planning grant awarded to investigators concerning a specific compound or combination of compounds. Designed to determine the clinical development plan and associated clinical trials needed to advance the compound to FDA approval for ASUD treatment. The protocol for the first study will be developed as part of the planning grant and will be considered for funding and implementation by the PASA Consortium.

**Funding Details:** $150,000 for 9-12 months.

**Additional Details**

**LOI Deadline:** April 22, 2019  
**Internal HRS Deadline:** April 19, 2019  
**Sponsor Deadline:** June 3, 2019

---

**Arthritis Society: Stars Career Development Award**

The Stars Career Development award has been created to firmly establish the career of early career investigators. This salary and research funding represents a three (3) year commitment by the Arthritis Society, together with an additional three (3) year commitment by the applicant’s Host Institution. The program is intended to promote creativity in all domains of arthritis-related research responsive to the Arthritis Society’s strategic priorities. Applicants should review the two research themes set out in the Arthritis Society’s 2015-2020 research strategy: (1) improving our understanding of arthritis and finding the cure, and (2) improving the care and management of arthritis.

**Funding Details:** The maximum award per application is $125,000 annually for up to three years ($375,000 total), with an additional 3 years of support from the Host Institution of an equal value. These awards are non-renewable. Please see additional details for more information.

**Additional Details**

**Abstract Registration Deadline:** May 22, 2019  
**Internal HRS Deadline:** June 12, 2019  
**Sponsor Deadline:** June 26, 2019

---

**Weston Brain Institute Rapid Response Parkinson’s & Related Diseases**
The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Transformational Research Program was created to provide seed funding to catalyze novel, high-risk, high-reward, translational research.

Projects must meet the following conditions to be eligible:

- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool

**Funding Details:** A max of $300,000 over up to 18 months per project.

**Additional Details**

**LOI Deadline:** March 13, 2019  
**Internal HRS Deadline:** July 2, 2019  
**Sponsor Deadline:** July 16, 2019

---

**Weston Brain Institute Transformational Research Parkinson’s & Related Diseases**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Transformational Research Program was created to provide significant support for larger, longer projects.

Projects must meet the following conditions to be eligible:

- Be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  - Clinical trials and clinical trial sub-studies should be submitted to the Early-Phase Clinical Trials or Rapid Response programs; however other translational research using humans or human samples/data is in scope.
- Be the development of a therapeutic and/or tool and/or complementary approaches

**Funding Details:** A max of $1,500,000 over a max of 3 years.

**Additional Details**

**LOI Deadline:** March 13, 2019  
**Internal HRS Deadline:** July 2, 2019  
**Sponsor Deadline:** July 16, 2019

---

**The Michael J. Fox Foundation Grants Therapeutic Pipeline Program**

The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care. Proposals must have a well-defined plan for moving toward clinical utility for Parkinson’s disease (PD) patients. The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications. Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program advances Parkinson's disease therapeutic and intervention development along the pre-clinical and clinical path (i.e., both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).

**Funding Details:** A maximum of $500,000 for 1 to 2 years.

**Additional Details**

**Pre-Proposal Deadline:** April 19, 2019  
**Internal HRS Deadline:** July 5, 2019  
**Sponsor Deadline:** July 19, 2019 (By invitation only)
The Michael J. Fox Foundation Grants: Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein

The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. These biofluids may include blood, cerebrospinal fluid, saliva and tears. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification.

- Immuno-assays should have a renewable source of the antibodies used. Optimization and/or adaptation of existent assays to different biological matrices will also be considered.
- Projects should propose to develop or optimize assays with superior performance in quantifying oligomeric alpha-synuclein and, at the end of the grant, should be able to present several performance parameters for further validation such as robustness, precision, trueness, uncertainty, limits of detection and quantification, dilutional linearity, parallelism, recovery, selectivity, and sample stability.

Funding Details: A maximum of $200,000 for 1 year.

Additional Details
Pre-Proposal Deadline: April 19, 2019
Internal HRS Deadline: July 5, 2019
Sponsor Deadline: July 19, 2019 (By invitation only)

The Michael J. Fox Foundation Grants: Biology of Astrocytes in Parkinson’s Disease

The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson’s disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson’s and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease.

Preference will be given to applications that focus on or include the following:
- Role of astrocytes in initiating and/or propagating Parkinson’s disease pathology, including alpha-synuclein spread, dopaminergic neuron death, inflammation and senescence
- Consequences of dysfunction and/or mutations of common PD targets, including alpha-synuclein, LRRK2, GBA, PRKN and PINK1
- Manipulation of astrocyte activity and/or astrocyte-specific pathways to assess the potential of targeted astrocyte therapies on disease biology and/or symptoms
- Parkinson’s disease models with high construct validity to human PD, including patient-derived material (such as iPSCs or cerebral organoids) and/or well characterized animal models and primary cells; Examination of human brain samples to answer specific hypotheses is also acceptable
- Targets, pathways and mechanisms proposed for investigation should have reasonable links to PD.

Funding Details: A maximum of $150,000 for 1 year to 18 months.

Additional Details
Pre-Proposal Deadline: April 19, 2019
Internal HRS Deadline: July 5, 2019
Sponsor Deadline: July 19, 2019 (By invitation only)

The Michael J. Fox Foundation Grants: Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy

The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, including positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI), none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD.

Applications must focus on developing robust and precise imaging markers.
- Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets.
- Imaging modalities can include PET, SPECT and MRI.
- Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets.
- Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques.

**Funding Details:** $750,000 for 1 to 3 years.

**Additional Details**

**Pre-Proposal Deadline:** April 19, 2019  
**Internal HRS Deadline:** July 5, 2019  
**Sponsor Deadline:** July 19, 2019 (By invitation only)

### Pharmacotherapies for Alcohol and Substance Abuse Consortium (PASA): Grant Program – (RFA) #4b

The goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). The PASA Consortium accepts applications for study funding during open solicitation periods. The exact number and type of studies approved during each solicitation period will depend on the quantity and quality of applications received and amount of available funding. Notices of study application solicitation periods will be posted here on the PASA Consortium’s website, publicly advertised via professional organization e-mail list serves and conference postings, and distributed to investigators, pharmaceutical companies, and academic research institutes that are known to have potentially viable candidate compounds.

Full study implementation awards for the conduct of proof-of-principle basic research to determine which compounds are most appropriate for human research trials.

**Funding Details:** $295,000 for 18 months.

**Additional Details**

**LOI Deadline:** May 13, 2019  
**Internal HRS Deadline:** July 8, 2019  
**Sponsor Deadline:** July 22, 2019

### Ontario Genomics: Genomics in Society Interdisciplinary Research Teams Program (GiSIRT)

Genome Canada has announced a Request for Applications (RFA) for the Genomics in Society Interdisciplinary Research Teams Program. This program aims to facilitate collaborations and dialogue among researchers and other key stakeholders to ensure effective and responsible translation of innovative genomics applications into sectors capable of transformation by genomics advances.

This program will support teams of researchers from diverse disciplines to address issues at the intersection of genomics and society. Research teams of at least three researchers from different disciplines investigating the advancement, adoption, evaluation, and governance of genomics research are encouraged to apply.

**Proposal Focus Areas**

- Stream 1: proposals mainly impacting the human health sector
- Stream 2: proposals mainly impacting the agriculture/agri-food and/or aquaculture/fisheries sectors
- Stream 3: proposals mainly impacting the natural resources (forestry, energy, mining) and/or environment sectors

Proposals that address multiple sectors across two or three streams are also eligible to apply.

**Funding Details:** There is approximately $3 million available from Genome Canada. Approximately one-third of the available Genome Canada funding will be invested in each of the three streams as defined above with the goal of funding at least one team in each of the three streams. Genome Canada will contribute between $500,000 and $1 million with the amount of co-funding from eligible sources at least equal to the Genome Canada contribution. Successful teams will be awarded funding for a term of up to four years.

**Additional Details**

**Registrations Deadline:** Draft Registrations: May 16, 2019. Final Registrations: May 27, 2019  
**Internal HRS Deadline:** August 9, 2019  
**Sponsor Deadline:** Draft Applications: June 27, 2019. Final Applications: August 23, 2019
**Canadian Cancer Society: Impact Grants**

The Impact Grant program supports significant progression in cancer research programs that are anywhere in the continuum from basic, high impact discovery to translational work of direct relevance to the clinic and beyond. Impact Grants aim to accelerate and focus the knowledge gained from scientific findings, in the short- to medium-term, into outcomes that will significantly advance understanding of cancer and improve scientific knowledge, which will result in optimized patient care, improved cancer treatment or reduced cancer burden. Impact Grants provide funding to support ideas that promote major advancements in research programs, whether at the fundamental discovery stage (such as studies involving model organisms that demonstrate potential for impact) through to applied research (such as patient or population-based proposals). Applications are encouraged from, but not limited to, the areas of biomedical, clinical, health services, and social and population health research.

Impact grants are not intended to support incremental scientific advances and are not intended to solely support research infrastructure.

Impact grants have been created to cultivate and support programs in cancer research that have the potential to make a significant impact on the burden of disease in patients and populations. The goal of the CCS Research Impact Grant program is to provide a mechanism for scientists to adopt innovations and accelerate the application of new knowledge to address problems in cancer research that have the potential for practical application.

**Funding Details:** There is one competition per year. It is anticipated that approximately 7 grants will be awarded in this competition. Note: Budgets awarded will not exceed $300,000 per year, to a maximum of $1,500,000 per grant. The grant term is up to 5 years. Grants will be renewable at the end of their term.

Funding will be provided to support the direct costs of a defined research program, including supplies, expenses, wages and equipment associated with the proposed work. Indirect costs will not be considered eligible expenses. Equipment requests of up to $150,000 can be included within the proposed budget.

**Additional Details**

**LOI Deadline:** April 17, 2019  
**Internal HRS Deadline:** August 27, 2019  
**Sponsor Deadline:** September 10, 2019

---

**Arthritis Society: Strategic Operating Grants**

The Strategic Operating Grant (SOG) program provides funding to support research proposals aligned with the Arthritis Society’s priorities. Consistent with the Arthritis Society’s 2015-2020 Research Strategy, Requests for Applications (RFAs) for SOGs will be made available by theme (typically one theme a year). The Arthritis Society will be accepting applications relevant to:

**Strategic Theme I: Improving our understanding of arthritis and finding the cure**

Research under this theme will seek to improve our understanding of the causes of arthritis in order to develop new approaches to alleviate the pain, prevent and/or slow the progression of disease, restore joint function, and eventually cure those affected by arthritis.

Research programs relevant to Strategic Theme I will have a main objective of:

- Understanding arthritis and arthritis pain pathophysiology and identifying therapeutic opportunities;
- Identifying and characterizing risk, and causal factors and/or development of arthritis and arthritis pain (including: biologic and endogenous factors; physical environment; and, psychological, social and economic factors);
- Discovering, developing and evaluating diagnostic (early detection), prognostic and predictive markers and technologies (such as imaging, diagnostic and other assessment tools) of disease (including: biomarker discovery and evaluation);
- Discovering, developing and evaluating potential therapeutic interventions in model systems and preclinical settings. (Including: pharmaceuticals; biologics; gene/cell/tissue therapies; medical devices; surgery (including joint replacement); and physical agents – including physical therapy, radiotherapy, ultrasound, laser and phototherapy).

**Funding Details:** The maximum grant per application is $120,000 annually for up to three (3) years ($360,000 total). These grants are non-renewable.

**Additional Details**

**LOI Deadline:** April 15, 2019  
**Internal HRS Deadline:** August 9, 2019  
**Sponsor Deadline:** August 25, 2019
A limited number of Travel Awards to PhD or MD/PhD students, and post-doctoral/medical/clinical fellows are available. The purpose of this program is to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting.

**Funding Details:** It is anticipated that up to 10 Travel Awards will be awarded in each competition (30 awards per year).

Note: Eligible expenses include: 1) Conference registration fees; 2) Accommodations; and 3) Transportation, and will not exceed $2,000.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis January 1, May 15 and September 15 annually.

---

**Canadian Cancer Society: Junior Investigator Grant Panel Travel Award**

Application guides can be found on the [EGrAMS documentation for applicants](#) page.

The Canadian Cancer Society is pleased to offer a special initiative to allow junior investigators in cancer research to gain knowledge and understanding of the Canadian Cancer Society peer-review process. During the year, through different funding opportunities, applications spanning all disciplines of cancer research are evaluated and ranked for funding.

Selected investigators from across Canada will be provided funds to reimburse travel costs to Toronto to observe a grant panel meeting. This unique opportunity will provide junior faculty members with an “inside look” at how research grants are reviewed in order to help structure their own grant proposals in future.

Selected investigators from across Canada will be provided funds to reimburse travel costs to Toronto to observe a grant panel meeting. This unique opportunity will provide junior faculty members with an “inside look” at how research grants are reviewed in order to help structure their own grant proposals in future.

Eligible applicants are investigators in cancer research at the end of their Post-doctoral fellowship or within the first few years of their academic appointment. Priority will be given to those who have yet to be awarded a grant from a Canadian granting agency. Applications for these limited funds will be accepted via [EGrAMS](#) and require Department or Institution Head sign-off prior to submission.

Please view the list of current grant panels for more information on available panels.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

---

**SickKids Foundation: Community Conference Grants**

The objective is to bring together families with researchers and clinicians for medical presentations, workshops, symposia and family-oriented discussions. The conference helps to ensure families receive access to the most up-to-date information regarding their children’s health. The grant will support events which are organized by and/or for families with children with health challenges, including, but not limited to children with acute illness, chronic illness and disabilities.

**Funding Details:** Awards are limited to an annual maximum request of $5,000. The Foundation will fund a maximum of three consecutive annual events organized by any single organization.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis January 31, May 31 and September 30 annually.

---

**Cancer Research Society: Translational Research Partnership Program**

The Translational Research Partnership Program supports collaborative projects in cancer research to help accelerate the development of new treatments and/or technologies for the benefit of patients. Our Translational Research Partnership strategy is bold and ambitious. We aim to break down the boundaries between research disciplines, which may include researchers from non-cancer backgrounds, in order to find innovative solutions to prevent, detect and treat cancer. We partner with a range of organizations to maximize the impact of research on patient outcomes.

Projects must meet the following conditions:

- Be translational research and may include clinical trial studies
- Basic research projects are out of scope
- Aim the development of a therapeutic and/or novel technologies
- Have excellent preliminary data to support the proposed project

The research team must consist of at least one principal investigator and one co-investigator. The inclusion of a variety of non-cancer disciplines is encouraged to drive the development of novel technologies and to take thinking from other fields that have not yet been applied to cancer.

All projects are evaluated based on the following criteria:
- Scientific excellence and innovativeness of proposed project
- Expertise of the multidisciplinary team
- Quality of preliminary data and feasibility
- Financial partner’s engagement
- Anticipated benefits for cancer patients

**Funding Details:** A maximum of $1,500,000 over up to 3 years per project of which up to 50% may come from the Cancer Research Society

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

**HHS: Clinical Health Professional Travel Awards**

The Clinical Health Professionals Research Travel Award provides support for eligible non-physician Health Professionals to present their work at a scientific meeting of relevance to their practice/research.

**Funding Details:** Up to six awards on a competitive basis will be given within a calendar year, and are each valued up to a maximum of $2,500 for a national conference or $3,500 for international (funds in Canadian dollars).

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

This funding program is led by Dr. Sandra Carroll, Director, Clinical Health Professional Research, carroll@mcmaster.ca. Interested candidates are recommended to contact Dr. Carroll or Daniela Bianco biancdn@hhsc.ca in advance of their submission. Please send inquiries to Donna Catherwood, catherwood@hhsc.ca.

**The Ontario HIV Treatment Network (OHTN), Endgame Funding Program: Community-Based Research and Evaluation (CBR&E) Awards**

The OHTN Community-Based Research & Evaluation Fund (CBR & E Fund) is designed to help achieve the mission of the OHTN; to improve the health and well-being of people living with and at risk of HIV in Ontario, through a network that promotes research and evidence to drive change. The CBR & E Fund will assist communities by supporting both the production and discovery of knowledge through community-based research, and the use of evidence to drive programming through participatory program evaluation.

OHTN is committed to funding scientifically rigorous, community relevant research that will have a short-to medium-term impact on those most affected by HIV in Ontario:

- People living with HIV/AIDS
- Gay men and other men who have sex with men, including gay, bi, and queer trans men, youth and newcomers
- African, Caribbean and Black men and women, including youth
- Aboriginal men and women, including youth
- Men and women who use drugs
- Women, including trans women, who are at risk (e.g. have unprotected sex or share drug equipment with people from the populations listed above)

The CBR & E fund will provide grant support to eligible community-initiated HIV research and evaluation projects that explore questions of importance to community-based organizations, and have the potential to have a meaningful impact on those most affected by HIV in Ontario in the next 2-5 years.

**Funding Details:** $25,000 to $50,000 for 1 year.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis March 1, June 7, September 6 and December 6, 2019.

**Ontario Brain Institute (OBI): Event Funding Program**

The Ontario Brain Institute (OBI) is committed to working together with brain health-related organizations in order to increase the capacity of their work in Ontario. The program especially looks to support events that embody OBI’s principles of integration and collaboration.

**Funding Details:** Up to $5,000.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis in January, May and September.
Crohn’s & Colitis Foundation: IBD Ventures
Is your organization engaged in the discovery or development of a novel product with the potential to help patients with inflammatory bowel diseases? If so, we want to hear from you!

The Crohn’s & Colitis Foundation seeks to accelerate the development of products that aim to improve the quality of life of patients with inflammatory bowel diseases. Toward that end, the Foundation has launched IBD Ventures, a new program and dedicated funding mechanism to support product-oriented research and development. Companies and academic investigators can apply.

**Funding Details:** Up to $500,000 per project per year will be considered. In addition, funded programs will be offered accelerator resources and advising.

**Additional Details**
**Sponsor Deadline:** Applications are being accepted on a rolling basis.

Ontario Genomics: Genomic Applications Partnership Program (GAPP)
The Genomic Applications Partnership Program (GAPP) funds downstream research and development (R&D) projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities. These organizations should be committed to commercializing or implementing the outcomes of the project.

Projects are led by the Receptor organization (Canadian or international) but are active collaborations with a Canadian academic researcher. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada.

The GAPP aims to:
- Accelerate the application of Canadian genomics-derived solutions from academia to real-world opportunities and challenges defined by industry, not-for-profit and public-sector Receptors.
- Channel Canada’s genomics capacity into sustainable innovations that benefit Canadians.
- Enhance the value of Canadian genomics technologies by de-risking and incentivizing follow-on investment from industry and other partners.
- Foster mutually beneficial collaboration and knowledge exchange between Canadian academia and technology receptors.

**Funding Details:** 1/3 investment from Genome Canada, 1/3 provided by the Receptor partner (cash and/or in-kind) and 1/3 of other co-funding (non-Genome Canada). For more information see Section 9 and Appendix 2 of the [GAPP Investment Strategy and Guidelines](#).

**Additional Details**
**LOI Deadline:** Accepted on a rolling basis February 19, May 20.

Weston Brain Institute Postdoctoral Scholars at Oxford
The Weston Brain Institute Postdoctoral Scholars at Oxford program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford.

**Funding Details:** £57,000 per year (£44,000 per year + benefits) for 2 years.

**Additional Details**
**Sponsor Deadline:** Applications are being accepted on a rolling basis, until 2 positions at a time are filled.

Weston Brain Institute International Fellowships: Canada
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Weston Brain Institute is pleased to launch our International Fellowships: Canada program. The program will support top Canadian PhD students to travel to and work in world-renowned international labs for up to 12 months, to further their translational research on neurodegenerative diseases of aging.

**Funding Details:** $60,000 per year, prorated at $5,000 per month to fit shorter travel and specific project needs.

**Additional Details**
**Sponsor Deadline:** Applications are being accepted on a rolling basis.

Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline
Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. More information here.

Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer’s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology.

Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

**Funding Details:** $50,000 to $100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis January 18, April 12, July 12, October 11.

**Sponsor Deadline:** Accepted on a rolling basis February 8, May 10, August 9, November 8.

**Alzheimer’s Drug Discovery Foundation: Drug Discovery Program**

The Alzheimer’s Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer’s disease, related dementias, and cognitive aging by supporting promising therapeutic approaches.

The Drug Discovery RFP supports:

- Novel drug programs aiming to advance novel lead molecules to the clinical candidate selection stage. This includes small molecules and biologics (e.g., antibodies, peptides, gene therapies).
- Repurposed/repositioned programs aiming to build preclinical evidence in relevant animal models for repurposed drugs (existing drugs that are approved for other diseases and conditions) and repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved).

**Funding Details:** $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis January 18, April 12, July 12, October 11.

**Sponsor Deadline:** Accepted on a rolling basis February 8, May 10, August 9, November 8.

**Alzheimer’s Drug Discovery Foundation: Neuroimaging & CSF Biomarker Development Program**

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology.

This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to:

- Clearly demonstrate target engagement for novel therapeutics
  The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.
- Detect signs of disease earlier and monitor progression
  We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This
includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer’s disease. We also seek prognostic markers that can predict rates of cognitive decline.

- More accurately diagnose and distinguish between dementia subtypes

Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.

**Funding Details:** $150,000-$600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis January 18, April 12, July 12, October 11.

**Sponsor Deadline:** Accepted on a rolling basis February 8, May 10, August 9, November 8.

**McMaster University, McMaster Institute for Research on Aging (MIRA), Canadian Longitudinal Study on Aging (CLSA): Call for Proposals**

The CLSA is a large, national, long-term study of more than 50,000 men and women who were between the ages of 45 and 85 when recruited. These participants will be followed until 2033, or death. The aim of the CLSA is to find ways to help us live long and live well, and understand why some people age in healthy fashion while others do not.

Researchers must notify Laura Harrington, Managing Director, MIRA, of their intent to apply for CLSA data access to be considered for MIRA funding. MIRA funds are allocated only to projects that do not have any other funding for this purpose.

MIRA membership is required to be eligible.

Data access applications are accepted three times per year.

**Funding Details:** MIRA can support access fees of $3,000 for a maximum 10 applications.


**Sponsor Deadline:** Ongoing

Please contact Audrey Patocs at patocsaemcmaster.ca with intent to apply or any inquiries. Applications will be handled through the MIRA office.

**McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities**

The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

**Funding Details:** Maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year.

**Additional Details**

**Sponsor Deadline:** Ongoing

Please contact Audrey Patocs at patocsaemcmaster.ca with intent to apply or any inquiries. Applications will be handled through the MIRA office.

**MITACS Globalink Research Award**

The Mitacs Globalink Research Award provides funding for senior undergraduate and graduate students, and postdoctoral fellows in Canada to conduct 12–24-week research projects at universities overseas. The following opportunities support travel and research from Canada to universities in:

Australia, Brazil, China, EU member countries: In France, both universities and Inria Research Centres are eligible host institutions, Israel, India, Japan, Korea, Mexico, Norway, Saudi Arabia, Tunisia, United Kingdom, United States.

**Funding Details:** $6,000 to conduct 12-24-week research projects at universities overseas.

**Additional Details**
Sponsor Deadline: Ongoing

**MITACS Accelerate Fellowship**
The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills. Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

**Funding Details:**
- **Master’s students** - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
- **PhD students** - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

**Weston Brain Institute: Big Ideas**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.

Based on success of previous programs, the Institute is expanding our support to new formats while maintaining the same mandate of accelerating the developments of therapeutics for neurodegenerative diseases of aging through translational research.

The Institute is considering supporting a large-scale, pivotal project to significantly advance research in our field. With this call, we are seeking to identify highly impactful ideas for consideration. Of particular interest are ideas that will establish Canada as the world leader in a particular area.

Goal: To support a large-scale, pivotal project that will significantly and sustainably advance research in the field of translational research on neurodegenerative diseases of aging.

**Funding Details:** From $5,000,000 to $20,000,000.

Additional Details
Sponsor Deadline: Ongoing

**Weston Brain Institute: Early Phase Clinical Trials: Canada**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above and can be working outside Canada.

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

Additional Details
Sponsor Deadline: Ongoing

**OCE Voucher for Innovation and Productivity II (VIP II) Program**
The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-secondary institutions’ skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.
Funding Details: The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000.

Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

MITACS Accelerate Program
Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

Funding Details: Funding starts at $15,000
Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP):
Exploration Hypothesis Development Award
The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.

The following are important aspects of the Exploration – Hypothesis Development Award:
- Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism.
- Impact: The primary goal of this mechanism is to pioneer transformative research that could lay the foundation for a new direction in the field of TSC.
- Feasibility: Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRP Exploration – Hypothesis Development Award will not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: April 18, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: April 25, 2019
Sponsor Deadline: May 9, 2019

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCR): Idea Development Award
The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale.

The following are important aspects of the Idea Development Award:
- Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care.
- Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative.
• Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are expected.

New Investigator Option: The FY19 TSCRP Idea Development Award mechanism encourages applications from investigators in the early stages of their TSC research career. The New Investigator Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed in separate groups. PIs applying under the New Investigator category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in TSC research and/or possessing other relevant expertise as demonstrated by a record of funding and publications.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRP Idea Development Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: April 18, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: April 25, 2019
Sponsor Deadline: May 9, 2019

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Clinical Translational Research Award

The Clinical Translational Research Award supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include studies moving from preclinical to clinical research (including a pilot clinical trial) and/or the reverse, analyzing human anatomical substances and/or data associated with clinical trials (such as correlative studies). Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest to the FY19 TSCRP.

Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. Preclinical studies may be appropriate but must include a clinical component. Projects that are exploratory and/or strictly animal research will not be considered for funding.

Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism can be found in the report of the National Cancer Institute Translational Research Working Group (http://clincancerres.aacrjournals.org/ content/14/18/5664.full). These pathways are comprehensive and span the entire translational research continuum from bench to bedside to bench.

The following are important aspects of the Clinical Translational Research Award:

• Translation: The application should clearly state how the proposed research project will expand upon promising, preclinical, and/or clinical research findings to move the field closer to a clinical application by the end of the study. If the proposed research includes both preclinical research and a pilot clinical trial, the application should explain how the preclinical research and pilot clinical trial aims are connected and necessary to advance the research toward clinical implementation.

• Impact: Proposed studies should have the potential to improve the diagnosis, prognosis, or treatment of TSC by: ○ Likely having a major impact on therapy by applying promising and well-founded laboratory or other preclinical or clinical research findings to the care of patients, and/or ○ Leveraging information from ongoing or completed clinical trials to address knowledge gaps in resulting outcomes, validate key research findings and expand upon potentially transformative results, or investigate novel findings.

• Feasibility: The application should demonstrate that the investigators have access to the necessary specimens, data, and/or intervention, as applicable.

• Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from the published literature that are relevant to TSC and the proposed research project, are required.

Projects including correlative studies: The FY19 TSCRP Clinical Translational Research Award may support correlative studies that are associated with an ongoing or completed clinical trial. The application should demonstrate access to the necessary specimens and/or data of the proposed cohort. Appropriate access must be confirmed at the time of application submission. See Attachment 10, Letter(s) Confirming Access to Specimens and/or Data. Projects including a pilot clinical trial: The FY19 TSCRP Clinical Translational...
Research Award may support a pilot clinical trial where limited clinical testing of a novel intervention is necessary to inform the next step in the continuum of translational research.

New FY19 definition for clinical trial: A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

The applicant conducting the trial must post an informed consent form used to enroll subjects on a publicly available Federal Web site in accordance with federal requirements (49 CFR Part 11).

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRCP Clinical Translational Research Award will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The CDMRP expects to allot approximately $1.92M to fund approximately two Clinical Translational Research Award applications.

**Additional Details**

**LOI Deadline:** April 18, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** April 25, 2019

**Sponsor Deadline:** May 9, 2019

**Department of Defense (DoD) Neurofibromatosis Research Program (NFRP): Clinical Trial Award**

The NFRP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Funding from this award mechanism must support a clinical trial. New FY19 definition: A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/ Program.htm. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY19 NFRP Program Announcements being offered.

If the proposed clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required. It is the responsibility of the applicant to provide evidence from the Institutional Review Board (IRB) of record or the FDA if an IND is not required. If an IND is required, the IND application must be submitted to the FDA by the FY19 NFRP Clinical Trial Award application submission deadline. The IND should be specific for the product (i.e., the product should not represent a derivative or alternate version of the investigational agent described in the IND application) and indication to be tested in the proposed clinical trial. For more information on IND applications, the FDA has provided guidance at https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/ investigationalnewdrugapplication/ default.htm.

If the investigational product is a device, then an Investigational Device Exemption (IDE) application to the FDA that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the FDA if an IDE is not required, or if the device qualifies for an abbreviated IDE. If an IDE is required, the IDE application must be submitted to the FDA by the Clinical Trial Award application submission deadline. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.

If the clinical trial of an investigational product will be conducted at international sites, evidence that an application to the relevant national regulatory agency of the host country(ies) has been submitted by the Clinical Trial Award application submission deadline is required.

Refer to Attachment 9, Regulatory Strategy, for additional details on documentation of FDA applications. The Government reserves the right to withdraw funding if an IND or IDE application is necessary but has not been submitted prior to the application submission deadline, or if documentation of an active IND or IDE in effect for the proposed trial has not been obtained within 6 months of the award date.
Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 NFRP Clinical Trial Award will not exceed $800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: May 23, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: May 23, 2019
Sponsor Deadline: June 6, 2019

Department of Defense (DoD) Neurofibromatosis Research Program (NFRP): Exploration – Hypothesis Development Award

The NFRP Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required.

The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of NF.

Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.104(d) (32 CFR 219.104(d)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record.

Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 NFRP Exploration – Hypothesis Development Award will not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: May 23, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: May 23, 2019
Sponsor Deadline: June 6, 2019

Department of Defense (DoD) Neurofibromatosis Research Program (NFRP): Investigator-Initiated Research Award

The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

Optional NF Open Science Initiative (NF-OSI): The FY19 NFRP supports the NF-OSI, which is aimed at catalyzing research for NF through early access to data and data sharing within the NF community.

- Participants in the NF-OSI will share data following the FAIR (Findable, Accessible, Interoperable and Reusable) Data Principles for reproducible science found in “The FAIR Guiding Principles for scientific data management and stewardship”:
  https://www.nature.com/articles/sdata201618.
- The NF Data Portal (http://www.nfdataportal.org/) is a central component of the NF-OSI and is intended as a format on which to share and explore NF datasets, analysis tools, resources, and publications. It is a public repository of raw data of scientific experiments that allows the re-analysis and confirmation of results by a third party.
  - The portal is not the place to share finalized results (these are generally publishable figures and related information), but rather any data point or image derived from experiments.
NF studies that involve generation of extensive data sets including, but not limited to, gene expression, genomic variants, methylation profiles, drug screening, drug combination screening, cellular physiology, chromatin activity, proteomics, imaging, kinomics, PK/PD, clinical studies, are highly encouraged to participate and utilize the NF Data Portal.

The portal allows participants to use the repository as their private data storage and selectively release the data to the public after an embargo period. For more information and requirements of participation, please visit http://www.nfdataportal.org/.

- Applications utilizing the NF-OSI option will be eligible to apply for Level 2 or Level 3 funding as described below.
- Applications utilizing the NF-OSI option must demonstrate their commitment to meeting the intent of the initiative in their Data Sharing Plan.
- Applications funded under the NF-OSI option will need to comply with data submission requirements that meets the intent of the initiative as a condition of continued funding for their project.

Optional Qualified Collaborator: The FY19 NFRP encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists. Collaborations with investigators outside of the Principal Investigator’s (PI’s) institution and collaborations that bring new perspectives from other disciplines or that bring new investigators into the NF field are strongly encouraged. Although more than one collaborator may participate in the application, only one can be named for this option.

Collaborations that meet the criteria below will qualify for a higher level of funding as described in Section II.D.5, Funding Restrictions. The PI must submit a Statement of Collaboration that clearly identifies the collaborating investigator and addresses how each of the criteria below are met. Additionally, the collaborator must provide a biographical sketch (see Research & Related Senior/Key Person Profile) and a letter of collaboration (see Attachment 9: Statement of Collaboration) describing his/her involvement in the proposed research project. It should be clear that the success of the proposed research project depends on the complementary skills and contributions of both the PI and collaborator.

- The collaborator must significantly contribute to the proposed research project such that it could not be accomplished without his/her involvement.
  - A proposed research project in which the collaborator merely supplies biological/ chemical materials, such as DNA/RNA constructs, purified or tagged proteins, chemical(s), transgenic mice, tissue samples or access to patients will not meet the intent of the Qualified Collaborator option and will not qualify for the higher level of funding.
  - A minimum of 10% level of effort for each budget period throughout the entirety of the award is required of the collaborator. The contributions of the collaborator should be reflected in the application’s budget.
- The collaborator must be at or above the level of Assistant Professor (or equivalent).

Preclinical Research: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in research and should be applied. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at https://www.elsevier.com/__data/promis_misc/622936arri...e_guidelines.pdf.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 NFRP Investigator-Initiated Research Award will not exceed one of the following funding levels: Level 1. Applications that do not include either of the two options qualify for the base level of funding at $525,000. Level 2. Applications that include either the Qualified Collaborator or the NF-OSI option: The anticipated direct costs budgeted for the entire period of performance will not exceed $575,000 for applications with either the Optional Qualified Collaborator or the Optional NFOSI. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate. Level 3. Applications that include both the Qualified Collaborator and the NF-OSI option: The anticipated direct costs budgeted for the entire period of performance will not exceed $625,000 for applications with both an Optional Qualified Collaborator and the Optional NFOSI. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate. The NFRP reserves the right to reduce funding levels
if applications submitted to either option do not meet the intent of either Level 2 or Level 3. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 23, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** May 23, 2019

**Sponsor Deadline:** June 6, 2019

**Department of Defense (DoD) Neurofibromatosis Research Program (NFRP): New Investigator Award**

The intent of the NFRP New Investigator Award is to support the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in the field of NF research. Prior experience in NF research is not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field.

Research projects may focus on any phase of research, excluding clinical trials. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 NFRP New Investigator Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 23, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** May 23, 2019

**Sponsor Deadline:** June 6, 2019

**Department of Defense (DoD) Neurofibromatosis Research Program (NFRP): Early Investigator Research Award**

The Early Investigator Research Award supports NF-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor. This opportunity allows for early-stage investigators to develop a research project, investigate a problem or question in NF research, and further their intellectual development as an NF researcher of the future. The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of NF research; however, the PI is not required to have previous NF research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in NF research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary Mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary Mentor with a more robust track record in NF research and mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as an NF researcher.

The PI must outline an individualized, NF-focused Researcher Development Plan. The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PI’s development as an independent NF researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PI’s institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-Mentor at the collaborating institution.

All application components for the Early Investigator Research Award are expected to be written by the PI, with appropriate direction from the Mentor(s). The NFRP seeks applications that address the critical needs of the NF community as outlined in the Areas of Emphasis above. If the project does not address an Area of Emphasis, provide justification that the proposed research project addresses an important problem in NF research and/or patient care. Describe the anticipated outcomes (short-term gains) from the proposed research and how they will be used as a foundation for future research projects. Explain the anticipated long-term gains from the proposed research project, including how the new understanding may ultimately contribute to the goal of advancing NF research and/or patient care.
The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 NFRP Early Investigator Research award will not exceed $200,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 23, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** May 23, 2019

**Sponsor Deadline:** June 6, 2019

### Department of Defense (DoD) Military Burn Research Program (MBRP): Idea Development Award

The MBRP Idea Development Award (IDA) mechanism is being offered for the first time in FY19. The intent of the FY19/20 MBRP IDA is to support highly impactful and military relevant research in the field of burn wound care. Applications proposing applied research and/or preclinical research will be considered for funding. Fundamental basic research and clinical studies will not be considered for funding.

Burns have comprised some 5%-20% of the casualties sustained in post-World War II conflicts. Potential future conflicts may cause a rise in the number of burn injuries sustained by Service members and the general public should those conflicts occur in rural areas, austere combat zones, and in mass casualty events, whereby medical resources are limited and/or access to medical care is delayed for hours, days, or weeks. In order to prepare the military and the Nation for such potential future conflicts, the FY19/20 MBRP is soliciting research to provide burn care solutions closer to the point of injury for the pre-hospital setting and for a prolonged field care scenario.

The North Atlantic Treaty Organization (NATO) defines prolonged field care (PFC) as field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care. PFC has been identified as a high priority capability gap across the Army and other Services. Additional information regarding PFC can be found in the following articles, Prolonged Field Care: Beyond the ‘Golden Hour’ 2 and Prolonged Field Care the New Normal says Army, MRMC Brass. 3

Although encouraged, applications submitted to the FY19/20 MBRP IDA are not required to address PFC. However, the proposed research must be relevant to active duty Service members and/or Veterans. Outcomes of funded projects are expected to also benefit military beneficiaries and the American public.

Inclusion of preliminary and/or published data relevant to the proposed research is required. To be competitive, the application must include a sound scientific rationale, logical reasoning, and a well-formulated, testable hypothesis.

**Funding Details:** The anticipated total costs budgeted for the entire period of performance for an FY19/20 MBRP IDA will not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 17, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** June 26, 2019

**Sponsor Deadline:** July 10, 2019

### Department of Defense (DoD) Military Burn Research Program (MBRP): Clinical Translational Research Award

The MBRP Clinical Translational Research Award (CTRA) is intended to support clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, preclinical, or clinical research findings to the care of the burn-injured patient.

Burns have comprised some 5%-20% of the casualties sustained in post-World War II conflicts. Potential future conflicts may cause a rise in the number of burn injuries sustained by Service members and the general public should those conflicts occur in rural areas, austere combat zones, and in mass casualty events, whereby medical resources are limited and/or access to medical care is delayed for hours, days, or weeks. In order to prepare the military and the Nation for such potential future conflicts, the FY19/20 MBRP is soliciting research to provide burn care solutions closer to the point of injury for the pre-hospital setting and for a prolonged field care scenario.

The North Atlantic Treaty Organization (NATO) defines prolonged field care (PFC) as field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care. PFC has been identified as a high priority capability gap across the Army and other Services. Additional information regarding PFC can be found in the following articles, Prolonged Field Care: Beyond the ‘Golden Hour’ 2 and Prolonged Field Care the New Normal says Army, MRMC Brass. 3
Although encouraged, applications submitted to the FY19/20 MBRP CTRA are not required to address PFC. However, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Funding from this award mechanism must support clinical research involving human subjects; animal research is not allowed under this funding opportunity. Principal Investigators (PIs) seeking funding for a preclinical research project should consider the FY19/20 MBRP Idea Development Award Program Announcement, if appropriate.

**Funding Details**: The anticipated total costs budgeted for the entire period of performance for an FY19/20 MBRP CTRA will not exceed $1.55M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline**: April 17, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline**: June 26, 2019

**Sponsor Deadline**: July 10, 2019

---

**Department of Defense (DoD) Parkinson's Research Program (PRP): Early Investigator Research Award**

The PRP EIRA supports Parkinson’s disease-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor. The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of Parkinson’s disease research; however, the PI is not required to have previous Parkinson's disease research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in Parkinson’s disease research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a Parkinson’s disease researcher.

The following are important aspects of the EIRA:

- All applications for the EIRA are to be written by the PI, with appropriate direction from the Mentor(s).
- Principal Investigator: The EIRA supports early-career investigators exploring innovative, high-impact ideas or new technologies applicable to Parkinson’s disease research and/or patient care. The PRP seeks applications from investigators working in a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. The application should demonstrate the PI’s potential for, and commitment to, pursuing a career in Parkinson’s disease research under the guidance of a designated Mentor(s). Evaluated criteria will include mentorship and the mentorship environment with an identified path to independence.
- Researcher Development Plan: The application must outline an individualized Parkinson’s disease-focused Researcher Development Plan. The Researcher Development Plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PI’s development as an independent Parkinson’s disease researcher. An environment appropriate to the proposed mentoring and research at the PI’s institution must be clearly described. Additional necessary resources and/or mentorship may be provided through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-Mentor at the collaborating institution.
- Focus Area: The proposed research must address at least one of the four FY19 PRP Focus Areas stated.
- Research Strategy and Feasibility: Experimental strategies may be novel or may be based on strong rationale derived from previously published data, presented preliminary data, or literature review. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Preliminary data are not required. Any unpublished, preliminary data provided should originate from the PI, Mentor(s), or member(s) of the collaborating team. The preliminary data must support the feasibility of the study.
- Impact: The proposed research, if successful, should impact an area of paramount importance in Parkinson’s disease. The application must clearly and explicitly describe the potential impact of the proposed study on Parkinson’s disease and convey its level of significance. The research should benefit individuals with Parkinson’s disease, by improving the understanding, prevention, diagnosis, and/or treatment of Parkinson’s disease.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details**: The anticipated total costs budgeted for the entire period of performance for an FY19 PRP EIRA award will not exceed $360,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
**Additional Details**

**LOI Deadline: July 9, 2019** (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline: July 10, 2019**

**Sponsor Deadline: July 24, 2019**

---

**Department of Defense (DoD) Parkinson's Research Program (PRP): Investigator-Initiated Research Award**

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson’s disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson’s disease or enhancing the wellbeing of individuals experiencing the impact of the disease.

The following are important aspects of the IIRA:

- **Research Strategy and Feasibility:** The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of Parkinson’s disease. Experimental strategies may be novel or may be based on strong rationale derived from previously published data, presented preliminary data, or literature review. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Preliminary data to support feasibility are required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. The preliminary data must support the feasibility of the study.

- **Impact:** The proposed research, if successful, should impact an area of paramount importance in Parkinson’s disease. The application must clearly and explicitly describe the potential impact of the proposed study on Parkinson’s disease and convey its level of significance. The research should benefit individuals with Parkinson’s disease, by improving the understanding, prevention, diagnosis, and/or treatment of Parkinson’s disease.

- **Focus Areas:** The proposed research must address at least one of the four FY19 PRP Focus Areas.

- **Principal Investigator and Research Team:** The PRP seeks applications from investigators working in a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. The application should demonstrate that the research team’s background is appropriate to successfully achieve the proposed research and contribute to the field of Parkinson’s disease research.

**Partnering PI Option:** The IIRA mechanism includes an option to fund a maximum of three PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) (maximum of two) will be identified as Partnering PI(s). Initiating and Partnering PIs each have different submission requirements, as described in Section II, Detailed Information About the Funding Opportunity; however, all PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work, and other required components. The Partnering PI Option requires a Synergy Statement (see Attachment 8). The Synergy Statement discusses in detail the advantages of addressing this problem through the combined expertise of the PIs and how this contributes to the synergy of the application. If recommended for funding, the Initiating PI and each Partnering PI will be named to an individual award within the recipient organization. The PI (and each Partnering PI) must maintain at least 15% dedication of his/her full-time professional effort during the award period to this award. The proposed partnership should result in a level of productivity that is greater than that achievable by each PI independently.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated total costs budgeted for the entire period of performance for an FY19 PRP Investigator-Initiated Research Award will not exceed $1.5M total costs for a single investigator or $2.4M combined total costs for the Partnering PI option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline: July 9, 2019** (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline: July 10, 2019**

**Sponsor Deadline: July 24, 2019**

---

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Pilot Award**

The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus.
on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models). The proposed research should include a testable hypothesis based on strong scientific rationale and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Inclusion of preliminary data is not required, but allowed. The strength of the application should be based on sound scientific rationale and logical reasoning. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Clinical trials will not be supported by this award mechanism. Innovation is the most important review criterion. Innovative ideas or approaches, if proven correct, will provide new paradigms or insights or technologies or applications that have the potential to meet the OCRP mission of supporting patient-centered research to prevent, detect, treat, and cure ovarian cancer.

The following list, although not all-inclusive, provides examples of research that is not innovative:

- Exploring a previously tested hypothesis in a different cell line or in a new population
- Using a published series of in vitro assays to further characterize a model system
- Incorporating known biomarkers into in vivo or clinical models of ovarian cancer
- Investigating the next logical step or continuation of a previous research project
- Proposing work that is an incremental advancement of published data

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Pilot Award will not exceed $250,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 23, 2019 *(A pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** July 10, 2019

**Sponsor Deadline:** July 24, 2019

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Investigator-Initiated Research Award**

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project.

The proposed research must be relevant to the health of active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Investigator-Initiated Research Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 23, 2019 *(A pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** July 10, 2019

**Sponsor Deadline:** July 24, 2019

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Ovarian Cancer Academy Award - Early-Career Investigator**

The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy (OCA) is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.

The OCA is a virtual career development and research training platform that consists of EarlyCareer Investigators (ECIs) and their Designated Mentors from different institutions, and an Academy Dean and Assistant Dean. The OCRP Ovarian Cancer Academy – Early-Career Investigator Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, Dean, Assistant Dean) as well as with the advocacy community. Since the inception of the Academy, the Academy’s ECIs have presented at and chaired sessions for ovarian cancer-specific symposia and served on symposia review committees. They have also served as peer reviewers for the Department of Defense (DoD) OCRP and other funding agencies.
The Academy Leadership, Dean and Assistant Dean, serves as a resource for the ECIs and Mentors, assessing the progress of the ECIs, and facilitating communication and collaboration among all of the ECIs and Mentors, as well as with national research and advocacy communities. In addition to fostering the scientific development, the Academy, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to fund and manage a productive laboratory. Information about the Academy is available through the Ovarian Cancer Academy video and OCRP Glitz Sheet on the OCRP website.

This FY19 Program Announcement/Funding Opportunity is soliciting additional ECIs to join the existing Academy. This award mechanism enables the ECI (the investigator named as the Principal Investigator [PI] on the application) to pursue an ovarian cancer project that may be basic, translational, and/or clinical research, or a clinical trial under the guidance of a Designated Mentor. The Designated Mentor is not required to be at the same institution as the ECI.

The OCRP encourages applications from ECIs whose ability to commit to conducting ovarian cancer research is limited by minimal resources or a lack of resources, such as a qualified Designated Mentor at his/her institution, access to ovarian cancer research tools, opportunities for establishing collaborations, or other obstacles.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from the ovarian cancer research field.

The ECI, who will be the PI of the application, must be in the early-career stage. This award provides the ECI with funding, networking and collaborative opportunities, and research experience necessary to develop and sustain a successful, independent career at the forefront of ovarian cancer research. This award also provides support and protected time for the ECI for 4 years of intensive research under the guidance of a Designated Mentor experienced in ovarian cancer research. Although the OCA will serve as a conduit to share knowledge and research experience among all Academy members, the ECI and Designated Mentor will be responsible for developing the ECI’s career development plans and for designing and executing the proposed research. The ECI must clearly articulate his/her commitment to a career as an ovarian cancer researcher and to participating in and contributing to the growth of the OCA.

The Designated Mentor must have a strong record of mentoring and training early-career investigators. In addition to being a Designated Mentor to an ECI, the Mentor must agree to serve as a secondary Mentor to another OCA-ECI. With the goal to expand and enrich the mentorship capabilities of the Academy, current OCA Designated Mentors can only be a Designated Mentor to one OCA-ECI; thus, current OCA Designated Mentors cannot be named as a Designated Mentor in an FY19 application unless the period of performance of the current OCA-ECI award ends no later than July 2020. In the same manner, the Dean and Assistant Dean of the Academy cannot be listed as Designated Mentors.

The ECI and Designated Mentor are required to attend a DoD OCRP biennial multi-day Academy workshop and, in alternate years, a DoD OCRP Academy 1-day workshop.

The proposed research must be relevant to the health of active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Ovarian Cancer Academy – Early-Career Investigator Award will not exceed $725,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 30, 2019 (A pre-application is required and must be submitted through eBRAP)  
**Internal HRS Deadline:** July 17, 2019  
**Sponsor Deadline:** July 31, 2019

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award**

The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy (OCA) is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.

The OCA is a virtual career development and research training platform that currently consists of 13 Early-Career Investigator (ECI)/Designated Mentor pairs from different institutions, and one Academy Dean and one Assistant Dean. Three ECIs will be graduating in the fall of FY19 and three FY18 OCA-ECI/Designated Mentor awards will be made by September 2019. In addition, eight have Academy graduates continue to participate in the annual Academy meetings. Information about the Academy is available in the
FY17 Ovarian Cancer Program Booklet at http://cdmrp.army.mil/ocrp/pbks/ocrppbk2017.pdf. The Academy Dean and Assistant Dean catalyze the growth and professional development of the ECIs in collaboration with their Designated Mentors, assess the progress of the ECIs, and facilitate communication and collaboration among all of the Academy members.

This FY19 Funding Opportunity is soliciting applications for an Academy Dean and Assistant Dean to lead the OCA for an anticipated start date in first quarter of FY20 – exact date to be determined. The Academy Dean and Assistant Dean (referred to as Academy Leadership) must be established ovarian cancer researchers, and can be at different institutions. Designated Mentors on FY19 Ovarian Cancer Academy – Early-Career Investigator Award applications and current Designated Mentors of Ovarian Cancer Academy – Early-Career Investigators (with the exception of those graduating in 2019) are not eligible to apply for this award. The Academy Leadership must demonstrate a strong record of mentoring and training junior investigators, a commitment to leadership, and the ability to objectively assess the progress of all of the ECIs in the OCA.

Responsibilities of the Academy Leadership include, but are not limited to:

- Act as a resource for all ECIs and Designated Mentors in the Academy over the 5-year period of performance as Academy Leadership.
- Facilitate communication and collaboration among all of the ECIs and Designated Mentors (including periodic interactive communication among all Academy members).
- Develop assessment criteria to evaluate the research progress made by all of the ECIs, as well as their career progression and sustainment as independent investigators in ovarian cancer research.
- Conduct collaborative ovarian cancer pilot project(s) that include Academy ECIs. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact ovarian cancer research and/or ovarian cancer patients/survivors.
- Provide constructive critiques with the goal of advancing the research and professional careers of the ECIs and strengthening the mentorship of the Designated Mentors.
- Provide avenues to increase the visibility of ECIs within the ovarian cancer research and advocacy communities (e.g., peer review, conferences, editorial boards).
- Support the professional development to include lab management skills, of the ECIs into leading researchers through invited presentations by experts outside of the OCA.
- Plan and host an annual 1-day workshop and biennially, a multi-day workshop for all ECI/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the OCA.
- Invite and financially support the travel for OCA graduates to attend the annual meetings, including them as speakers and participants.
- Assemble an Advisory Board to the Academy to include Academy alumni.

The Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award is structured to support two Principal Investigators (PIs). The Academy Dean will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Assistant Dean will be identified as the Partnering PI. The collaboration between the Academy Dean and the Assistant Dean should be supported by complementary expertise and experience. Initiating and Partnering PIIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to continue the success of ECIs. While it is up to the Academy Dean and the Assistant Dean to define their roles, both Academy Leaders should have interactions with the ECIs; acting as administrative support does not fulfill the intent of the Assistant Dean. If recommended for funding, each PI will be named to an individual award within the recipient organization.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for the Initiating PI (Academy Dean) and the Partnering PI (Assistant Dean) awards for the entire 5-year period of performance for the FY19 OCRP Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award will not exceed $1.75M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 30, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 17, 2019

**Sponsor Deadline:** July 31, 2019

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Clinical Development Award**
The OCRP Clinical Development Award is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Proof of concept demonstrating the potential utility of the proposed product or a prototype/ preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required.

New FY19 definition: A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available Federal website in accordance with Federal requirements described in 32 CFR 219.

Important aspects of the application to the FY19 OCRP Clinical Development Award:
- The application should demonstrate availability of, and accessibility to, a suitable human subject population or anatomical samples that will support a meaningful outcome for the study, discussion of feasibility of the proposed study, and how accrual goals will be achieved.
- The application should demonstrate documented availability of, and accessibility to, the drug/compound, device, and/or materials needed.
- The proposed study should include clearly defined and appropriate endpoints.
- The application should include a detailed statistical analysis plan, including a power analysis reflecting sample size projections that will clearly answer the objectives of the study.
- Applications must also include a transition plan (including potential funding and resources) showing how the result will progress to the next level of development (e.g., future clinical trials, delivery to the military or civilian market) after the completion of the OCRP award.
- Applications are encouraged to include diversity in their sample populations.

Optional Nested Early-Career Investigator: For Principal Investigators (PIs) that are proposing clinical trials, this FY19 OCRP Clinical Development Award mechanism is offering an optional nested Early-Career Investigator to foster the next generation of ovarian cancer investigators in the conduct of clinical trials. One Early-Career Investigator can be named within a given application, and the Early-Career Investigator must be within 5 years of his/her last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the full application submission deadline. The Early-Career Investigator must meet specific eligibility criteria as described in Section II.C, Eligibility Information. Applications that contain a nested Early-Career Investigator will qualify for a higher level of funding as described under Section II.D.5, Funding Restrictions. The PI on the Clinical Development Award must mentor the nested Early-Career Investigator.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191.

Relevance to Military Health: The proposed research must be relevant to the healthcare needs of military Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Clinical Development Award will not exceed $600,000, and the anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Clinical Development Award with an optional nested Early-Career Investigator will not exceed $800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The Government reserves the right to fund an application at a lower funding level if it does not meet the eligibility criteria or intent of the optional feature.

**Additional Details**

**LOI Deadline:** April 30, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 17, 2019

**Sponsor Deadline:** July 31, 2019

**Department of Defense (DoD) Autism Research Program (ARP): Clinical Trial Award**

The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. It is expected
that the proposed clinical trial begins no later than 12 months after the award date, or 18 months after the award date for U.S. Food and Drug Administration (FDA)-regulated studies.

New FY19 definition: A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY19 ARP Program Announcements being offered. The term “human subjects” is used in this Program Announcement to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm.

PIs seeking funding for a preclinical research project should consider the FY19 ARP Idea Development Award (Funding Opportunity Number: W81XWH-19-ARP-IDA). Further, PIs seeking funding for the initial development and proof-of-principle testing of an intervention, and not a robust statistically powered clinical trial, should consider the FY19 ARP Clinical Translational Research Award (Funding Opportunity Number: W81XWH-19-ARP-CTRA).

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

If the proposed clinical trial involves the use of a drug that has not been approved by the U.S. FDA for the proposed investigational use, then an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required. It is the responsibility of the applicant to provide evidence from the Institutional Review Board (IRB) of record or the FDA if an IND is not required. If an IND is required, the IND application must be submitted to the FDA by the Clinical Trial Award application submission deadline. The IND should be specific for the product (i.e. the product should not represent a derivative or alternate version of the investigational agent described in the IND application) and indication to be tested in the proposed clinical trial. For more information on IND applications, the FDA has provided guidance at https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/InvestigationalNewDrugIndApplication/default.htm.

If the investigational product is a device, then an Investigational Device Exemption (IDE) application to the FDA that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the FDA if an IDE is not required, or if the device qualifies for an abbreviated IDE. If an IDE is required, the IDE application must be submitted to the FDA by the Clinical Trial Award application submission deadline. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.

If the clinical trial of an investigational product will be conducted at international sites, evidence that an application to the relevant national regulatory agency of the host country(ies) has been submitted by the Clinical Trial Award application submission deadline is required.

Refer to Attachment 8, Regulatory Strategy, for additional details on documentation of FDA applications. The Government reserves the right to withdraw funding if an IND or IDE application is necessary but has not been submitted prior to the application submission deadline, or if documentation of an active IND or IDE in effect for the proposed trial has not been obtained within 6 months of the award date.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 ARP Clinical Trial Award will not exceed $1,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 1, 2019 *(A pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** July 25, 2019

**Sponsor Deadline:** August 8, 2019

**Department of Defense (DoD) Autism Research Program (ARP): Idea Development Award**

The ARP Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with ASD. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.
Important aspects of the FY19 ARP Idea Development Award are as follows:

- **Impact:** The proposed research is expected to make an important and original contribution to advancing the understanding of ASD and ultimately lead to improved outcomes for individuals with ASD. The project’s impact on both ASD research and patient care should be articulated, even if clinical impact is not an immediate outcome. A statistical plan is an important aspect of the FY19 ARP Idea Development Award to demonstrate the significance of any research outcomes or findings.

- **Innovation:** Research deemed innovative may represent a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research may be innovative in study concept, research methods or technology, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative.

- **Personnel:** Personnel are considered a crucial element of the FY19 ARP Idea Development Award. The study team should have experience in ASD research. A biostatistician should be included in the study team.

- **Research must be based on preliminary data:** Although the proposed research must have direct relevance to ASD, the required preliminary data, which may include unpublished results from the laboratory of the Principal Investigators (PIs), research team, or collaborators named on the application, may be from outside the ASD research field. Research should also be based on a sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 ARP Idea Development Award will not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 1, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 25, 2019

**Sponsor Deadline:** August 8, 2019

**Department of Defense (DoD) Autism Research Program (ARP): Clinical Translational Research Award**

The ARP Clinical Translational Research Award is intended to support early-phase, proof-of-principle translational studies that will examine hypothesis-based, innovative interventions that have the potential to address current clinical deficits for ASD. Applications are strongly encouraged to address one of the ARP Clinical Translational Research Award Areas of Interest. If the proposed project does not address any of the FY19 ARP Clinical Translational Research Award Areas of Interest, the application should describe how the project will nevertheless address a critical need of the ASD community. Outcomes from studies funded by this award are anticipated to provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform ASD clinical care.

Projects are required to involve human subjects. Projects that are strictly animal research aimed at developing or refining new technology and research to establish the efficacy/ effectiveness of diagnostic agents are not allowed under this funding opportunity. The proposed studies should include early-phase, proof-of-principle studies using human subjects. The proposed studies may be interventional, including Phase 0 clinical trials or single-group intervention studies, and may involve some retrospective data analysis; however, purely retrospective or database-related research is not allowed.

**New FY19 definition:** A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Principal Investigators (PIs) seeking funding for a larger clinical trial should consider the ARP Clinical Trial Award (Funding Opportunity Number: W81XWH-19-ARP-CTA). Likewise, PIs seeking funding for a preclinical research project should consider the ARP Idea Development Award (Funding Opportunity Number: W81XWH-19-ARP-IDA).

For applications that include a clinical trial, the Investigational New Drug (IND)/Investigational Device Exemption (IDE) Documentation (Attachment 11) should be included. If the clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, evidence that an IND exemption application that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) has been submitted or will be submitted to the FDA within 90 days of award is required. If the investigational product is a device, evidence that an IDE application that meets all requirements under 21 CFR 812 has been submitted or will be submitted to the FDA within 90 days of award, or that the device is exempt from an IDE, is required. The Government reserves the right to withdraw funding if the IND or IDE application has not been submitted to the FDA within 90 days of the Department of Defense (DoD) award date or if the documented status of the IND or IDE has not been obtained within 9 months of the award date.
Research must be based on preliminary data. Although the proposed research must have direct relevance to ASD, the required preliminary data, which may include unpublished results from the laboratory of the PI, research team, or collaborators named on this application, may be from outside the ASD research field.

The following are important aspects of the research to be funded by the Clinical Translational Research Award:

- The research should include clearly defined and appropriate endpoints.
- The research should include a statistical analysis plan that will clearly answer the objectives of the study. Robust statistically powered efficacy studies are not expected at this stage of research and development.
- A transition plan (including potential funding and resources) must be included showing how the research findings or intervention will progress to the next level of development (e.g., future clinical trials) after the completion of the FY19 ARP Clinical Translational Research Award.
- The proposed clinical research must be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.
- If applicable, documentation of an existing IND or IDE must be included.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 ARP Clinical Translational Research Award will not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 1, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 25, 2019

**Sponsor Deadline:** August 8, 2019

**Department of Defense (DoD) Lung Cancer Research Program (LCRP): Career Development Award**

The FY19 LCRP Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.

Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.

Key elements of this award are as follows:

- Principal Investigator (PI): PIs must be research- or physician-scientists at an early stage of their independent research careers. PIs must be within 5 years of their first faculty appointment (or equivalent) and exhibit a strong desire to pursue a career in lung cancer research.
- Mentorship: The Mentor must be an experienced lung cancer researcher as demonstrated by a strong record of funding and publications in lung cancer research. In addition, the Mentor must demonstrate a commitment to developing the PI’s career in lung cancer research.
- Career Development: A Career Development Plan is required and should be prepared with appropriate guidance from the Mentor. A clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of lung cancer research should be included. The plan should outline how the PI will gain experience in lung cancer research. Because career development is the focus of this award, the PI’s institution must demonstrate a commitment to the PI through a minimum of 40% protected time for lung cancer research, though more protected time is highly desirable.
- Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating deaths and suffering from lung cancer.
- Relevance to Military Health System Beneficiaries: The application should clearly articulate how the proposed research is relevant to Service members, Veterans, and their families.

Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

- Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
- Collaboration with DoD or VA investigators
Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area

Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population

Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other Military Health System beneficiaries, including environmental exposures other than tobacco

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 LCRP Areas of Emphasis.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the general public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 LCRP Career Development Award will not exceed $250,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** August 1, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 7, 2019

**Sponsor Deadline:** August 21, 2019

### Department of Defense (DoD) Lung Cancer Research Program (LCRP): Idea Development Award

The FY19 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Applications should include a well formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.

New Investigators: The FY19 LCRP Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment, or equivalent). The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI’s expertise to best address the research question. All applicants for the New Investigator category must meet specific eligibility criteria as described in Section II.C, Eligibility Information.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer. Key elements of this award are as follows:

**Innovation:** Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.

**Impact:** Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating deaths and suffering from lung cancer.

It is the responsibility of the PI to clearly and explicitly articulate the project’s innovation and its potential impact on lung cancer and its relevance to Military Health System beneficiaries. The project’s impact to both lung cancer research and to lung cancer patients should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the Idea Development Award.

**Relevance to Military Health:** The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

- Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
- Collaboration with DoD or VA investigators
Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area

Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population

Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other Military Health System beneficiaries, including environmental exposures other than tobacco

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Congressionally mandated Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 LCRP Areas of Emphasis.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 LCRP Idea Development Award will not exceed $350,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details

LOI Deadline: May 15, 2019 (A pre-application is required and must be submitted through eBRAP)
Sponsor Deadline: August 21, 2019
Internal HRS Deadline: August 7, 2019

Department of Defense (DoD) Lung Cancer Research Program (LCRP): Investigator Initiated Translational Research Award

The FY19 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:

• Studies advancing/ translating in vitro and/or animal studies to applications with human samples/cohorts.
• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission.
• Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required.

Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

• Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
• Collaboration with Department of Defense (DoD) or Veterans Affairs (VA) investigators
• Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
• Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
• Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other Military Health System beneficiaries, including environmental exposures other than tobacco
Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 LCRP Areas of Emphasis.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 LCRP Investigator-Initiated Translational Research Award will not exceed $400,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 15, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 7, 2019

**Sponsor Deadline:** August 21, 2019

**Department of Defense (DoD) Lung Cancer Research Program (LCRP): Translational Research Partnership Award**

The FY19 LCRP Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a central problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a Department of Defense (DoD) military treatment facility or laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.

Observations that drive a research idea may be derived from a laboratory discovery, population based studies, or a clinician’s firsthand knowledge of patients and anecdotal data. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, members of the partnership should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:

- Studies advancing/translating in-vitro and/or animal studies to applications with human samples/cohorts.
- Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission.
- Pilot, proof-of-principle clinical trials (must include documentation of an existing IND or Investigational Device Exemption (IDE), if applicable).
- Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials.

The success of the project must be supported by the unique skills and contributions of each partner. The proposed study must include clearly stated plans for interactions between the Principal Investigators (PIs) and institutions involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required. Clinical trials are supported by this award mechanism and, if proposed, require the submission of Attachment 8, Human Subject Recruitment and Safety Procedures.

**Relevance to Military Health:** The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the
DHP and FY19 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

- Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research.
- Collaboration with DoD or VA investigators.
- Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area.
- Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.
- Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other Military Health System beneficiaries, including environmental exposures other than tobacco.

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 LCRP Areas of Emphasis.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

The Translational Research Partnership Award mechanism requires two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work, and other required components. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. If recommended for funding, each PI will be named to an individual award within the recipient organization.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 LCRP Translational Research Partnership Award will not exceed $900,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 15, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 7, 2019

**Sponsor Deadline:** August 21, 2019

### Department of Defense (DoD) Tick-Borne Disease Research Program (TBDRP): Career Development Award

The FY19 TBDRP Career Development Award supports independent, early-career investigators in their efforts to conduct impactful research with the mentorship of an experienced tick-borne diseases researcher (i.e., the Mentor), thus providing an opportunity to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of tick-borne diseases research. This award supports impactful research projects with an emphasis on discovery that may be translational in nature, but are not clinical trials. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI’s research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Mentor. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. The following are key aspects of the FY19 TBDRP Career Development Award:

- **Principal Investigator:** The PI must be an early-career research scientist or physician scientist within 10 years of completion of his/her terminal degree (excluding time spent in residency or on family medical leave). The PI’s record of accomplishments and the proposed research will be evaluated regarding his/her potential for contributing to the field of tick-borne diseases research. Because career development is the focus of this award, the PI’s institution must demonstrate a commitment to the PI through a minimum of 75% protected time for tick-borne diseases research, although more protected time is highly desirable.

- **Mentorship:** The Mentor must be an experienced tick-borne diseases researcher as demonstrated by a proven record of funding and publications in tick-borne diseases research. The Mentor must hold a position at or above the level of an
The following are key aspects of the FY19 TBDRP IIRA:

- Career Development Plan: A career development plan is required and should be prepared by the PI with appropriate guidance from the Mentor. A clearly articulated strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne diseases research should be included. The plan should outline how the PI will gain experience in tick-borne diseases research.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 TBDRP Career Development Award will not exceed $250,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

LOI Deadline: **May 22, 2019** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **August 8, 2019**
Sponsor Deadline: **August 22, 2019**

**Department of Defense (DoD) Tick-Borne Disease Research Program (TBDRP): Idea Award**

The FY19 TBDRP Idea Award intends to support conceptually innovative, high-risk/potentially high-reward research in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses. This award mechanism promotes new ideas that represent innovative approaches to Lyme disease and other tick-borne diseases research and have the potential to make an important contribution toward the TBDRP mission. Applications should include a well-formed, testable hypothesis based on strong scientific rationale that is established through inferential reasoning and/or critical review and analysis of the literature.

The following are key aspects of the FY19 TBDRP Idea Award:

- Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to Lyme disease and other tick-borne diseases research. Research that is merely an incremental advance (the next logical step) is not considered innovative.
- Relevance: Applications should articulate how the proposed research is relevant to at least one of the FY19 TBDRP Focus Areas. Highly relevant research will address the current evidence-based burden of disease on public health, while also considering the healthcare needs and welfare of military Service members and their families.
- Preliminary Data: Due to this award’s emphasis on innovation, inclusion of preliminary data, such as unpublished data from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from published literature that are relevant to Lyme disease and other tick-borne diseases and support the proposed research project, is encouraged, but not required.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 TBDRP Idea Award will not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

LOI Deadline: **May 22, 2019** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **August 8, 2019**
Sponsor Deadline: **August 22, 2019**

**Department of Defense (DoD) Tick-Borne Disease Research Program (TBDRP): Investigator-Initiated Research Award**

The FY19 TBDRP Investigator-Initiated Research Award (IIRA) intends to support highly rigorous, high-impact studies that have the potential to make important contributions to Lyme disease and other tick-borne diseases research, patient care, and/or quality of life. This award mechanism promotes a wide range of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial to establish proof-of-principle for further development in future studies. Applications should include a well-formed, testable hypothesis based on strong scientific rationale that is established through logical reasoning, preliminary data, and critical review and analysis of the literature.

The following are key aspects of the FY19 TBDRP IIRA:

- Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance Lyme disease and/or other tick-borne diseases research, patient care, and/or quality of life.
• Relevance: Applications should articulate how the proposed research is relevant to at least one of the FY19 TBDRP Focus Areas. Highly relevant research will address the current evidence-based burden of disease on public health, while also considering the healthcare needs and welfare of military Service members and their families.

• Preliminary Data: Inclusion of preliminary data, such as unpublished data from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from the published literature that are relevant to Lyme disease and other tick-borne diseases and support the proposed research project, is required.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 TBDRP Investigator-Initiated Research Award will not exceed $650,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 22, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 8, 2019

**Sponsor Deadline:** August 22, 2019

---

**Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Career Development Award**

The FY19 PRCRP Career Development Award supports independent, early-career investigators to conduct impactful research with the guidance of an experienced cancer researcher (i.e., Career Guide). The Career Development Award presents an opportunity for early-career investigators to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of cancer research. This award supports impactful research projects with an emphasis on discovery. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Career Guide. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.

**Key elements of the Career Development Award mechanism are as follows:**

- **Principal Investigator:** The PI must be an independent, early-career researcher or physician-scientist within 10 years after completion of his/her terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Postdoctoral fellows are not considered independent and are not eligible for this award mechanism. The PI’s record of accomplishments and the proposed research will be evaluated regarding his/her potential for contributing to the FY19 PRCRP Topic Area(s) in Section II.A.1. Previous and/or current career development funding outside of institutional startup funds will be taken into consideration when evaluating an applicant’s need for further developmental funds. Because career development is the focus of this award, the PI’s organization must demonstrate a commitment to the PI through confirmation of laboratory space and at least 50% protected time for cancer research.

- **Career Development Plan:** A career development plan is required and should be prepared with appropriate guidance from the Career Guide. The Career Guide must be an experienced cancer researcher as demonstrated by a strong record of funding and publications. In addition, the Career Guide must demonstrate a commitment to advancing the PI’s career in cancer research. The career development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise to advance an independent career at the forefront of cancer research in at least one of the FY19 PRCRP Topic Areas.

- **PRCRP Topic Areas:** The proposed research must address at least one of the FY19 PRCRP Topic Areas.

- **Relevance to Military Health:** The proposed research must address at least one of the FY19 PRCRP Military Health Focus Areas in Section II.A.2. The proposed research must be relevant to active duty Service members, Veterans, and their beneficiaries. For more information, review the following websites:
  - PRCRP (https://cdmrp.army.mil/prcrp/default)
  - PRCRP Report to Congress (https://cdmrp.army.mil/prcrp/reports/reports)
  - Military Health System (https://www.health.mil/)
  - VA (https://www.va.gov/)

- **Impact:** The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient care. Impactful research will, if successful, accelerate the movement of promising ideas in cancer research into clinical applications.

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-
Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Horizon Award

The FY19 PRCRP Horizon Award supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor). The intent of the Horizon Award is to recruit junior-level scientists to perform research in one of the FY19 PRCRP Topic Areas. The Horizon Award challenges junior scientists to develop and implement research in the cancer field. This opportunity allows for junior investigators to develop a research project, investigate a problem or question in the field of cancer, and further their intellectual development as a cancer researcher of the future. Under this award mechanism, the junior investigator is considered the Principal Investigator (PI), and the application should focus on the PI’s research and career development. It should be clear that the proposed research is intellectually designed by the PI with assistance from the Mentor. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. Clinical trials will not be supported by this mechanism.

Key elements of the Horizon Award are as follows:

- **Principal Investigator:** Both predoctoral candidates and postdoctoral fellows are eligible according to the following definitions:
  - A predoctoral candidate within 2 years of completing required graduate coursework, having completed all laboratory rotations, successfully passed qualifying examinations (excluding time in residency, clinical training, or on family medical leave), and is working in his/her Mentor’s laboratory by the time of the application submission deadline.
  - A postdoctoral fellow within 3 years of completion of his/her terminal degree (excluding time in residency, clinical training, or on family medical leave) and working in the Mentor’s laboratory at the time of the application submission deadline.

- **Mentor:** The Mentor must be an experienced cancer researcher as demonstrated by a strong record of active funding and publications. In addition, the Mentor must demonstrate a commitment to advancing the PI’s career in cancer research. The Mentor’s record of accomplishments (such as publications, patents, presentations, etc.) should include documentation of significant contribution to cancer research. If the Mentor is not a researcher in the selected FY19 PRCRP Topic Area of the PI, it is strongly recommended that a collaborator or co-Mentor be named.

- **PRCRP Topic Areas:** The proposed research must address at least one of the FY19 PRCRP Topic Areas in Section II.A.1.

- **Research Approach:** The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved.

- **Researcher Development Plan:** A researcher development plan is required and should be prepared with appropriate guidance from the Mentor. The application should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise to successfully complete the proposed cancer research in at least one of the FY19 PRCRP Topic Areas in Section II.A.1. A commitment of 100% effort by the PI is required for the proposed research. If the PI is a predoctoral candidate, the proposed research should be in the topic of the PI’s thesis.

- **Impact:** The proposed research should have the potential for significant impact on at least one of the FY19 PRCRP Military Health Focus Areas in one of the FY19 PRCRP Topic Areas.

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-
The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details**: The anticipated direct costs budgeted for the entire period of performance for an FY19 PRCRP Horizon Award will not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

---

**Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Idea Award with Special Focus**

The FY19 PRCRP Idea Award with Special Focus supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. The “Special Focus” of this award mechanism is on exposures, conditions, or circumstances that are unique to the military, disproportionately represented in a military beneficiary population, or may affect force readiness. Cancers or circumstances with cancer risk that may affect the Service members’ support system (military families) are of special importance for total mission readiness. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to active duty Service members, Veterans, other military beneficiaries, and the American public. Relevance to military health should be articulated with respect to the overall MHS, the FY19 PRCRP Military Health Focus Areas in Section II.A.2, and the mission of the DHP and the FY19 PRCRP. For more information, review the following websites:

- PPRC (https://cdmrp.army.mil/prcrp/default)
- PPRC Report to Congress (https://cdmrp.army.mil/prcrp/reports/reports)
- Military Health System (https://www.health.mil)
- VA (https://www.va.gov)

The Idea Award with Special Focus is not intended to support a logical progression of an already established research project. The proposed research should be innovative. A key characteristic of this funding opportunity is innovation. Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Incremental advances, the next logical step, or switching a model system from one cancer to another cancer is not considered innovative. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. It is the responsibility of the Principal Investigator (PI) to select the funding opportunity that is most appropriate for the research proposed. For studies with strong preliminary data that support the next step in research, please consider the FY19 PRCRP Impact Award (W81XWH-19-PRCRP-IPA).

Inclusion of preliminary data is not required. This award is not intended to support ongoing research in the applicant’s laboratory; therefore, inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory nature of this award. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects to understand the mechanisms of initiation or progression of cancer, the quality of life during and following cancer treatment, etc.

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 PRCRP priorities.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details**: The anticipated direct costs budgeted for the entire period of performance for an FY19 PRCRP Idea Award with Special Focus will not exceed $400,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Impact Award

The FY19 PRCRP Impact Award supports hypothesis-driven, high-impact research. The Impact Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on at least one of the FY19 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations for finding cures in under-funded, under-studied, and/or lethal militarily relevant cancer or research areas. With the Impact Award, PRCRP offers the unique opportunity to find commonalities in research across multiple cancers that advance the broader cancer field and to address cancer funding disparities within the FY19 PRCRP Topic Areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact.

The critical components of this award mechanism are:

- **Impact:** The Impact Award is intended to support research that demonstrates the potential to have a major impact on an area of paramount importance in cancer. The proposed study should demonstrate how the research will transform cancer research toward improved patient care in at least one of the FY19 PRCRP Topic Areas and has potential near-term outcomes. The research should make a significant shift toward clinical applicability in at least one of the FY19 PRCRP Topic Areas. Research should challenge paradigms with respect to the endpoint of impact on patient care and outcomes. Proposed projects may include translational or clinical research, including clinical trials. The potential impact of the proposed research is expected to be near-term and it must be significant and go beyond an incremental advance. The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient care. Impactful research will, if successful, accelerate the movement of promising ideas into clinical applications. The Impact Award is not intended for basic research.

- **Preliminary Data:** The Impact Award is intended to support transformative investigations that leapfrog the cancer research field forward by utilizing previous research findings. Applications must include preliminary data to support feasibility of the study. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team.

- **Continuity of Research:** The Impact Award is intended to support established projects that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.

- **Military Relevance:** The proposed research must address at least one of the FY19 PRCRP Military Health Focus Areas. The proposed research must be relevant to active duty Service members, Veterans, and their beneficiaries. For more information, review the following websites:
  - PRCRP (https://cdmrp.army.mil/prcrp/default)
  - PRCRP Report to Congress (https://cdmrp.army.mil/prcrp/reports/reports)
  - Military Health System (MHS) (https://www.health.mil)
  - VA (https://www.va.gov/)

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 PRCRP priorities. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 PRCRP Impact Award will not exceed $1,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details

**LOI Deadline:** May 22, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 28, 2019

**Sponsor Deadline:** September 11, 2019

Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP): Translational Team Science Award
The FY19 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with a clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings.

New for FY19: The FY19 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required):

- Interventions to improve quality of life for cancer patients and/or survivors
- Cancer prevention or early detection
- Understanding metastatic disease to improve outcomes

Applications proposing a study not within the scope of the FY19 PRCRP TTSA Areas of Emphasis must demonstrate that the research proposed once translated to the clinic will have lasting impact in the research area studied.

The TTSA may support studies in animal models, human subjects, and human anatomical substances. Accordingly, development or use of relevant preclinical models may be included. The TTSA is not intended to support high-throughput screenings, sequencing, etc.

Important aspects of the TTSA mechanism are as follows:

- Collaboration: The success of the project depends on the unique skills and contributions of each collaborator. At least two, and up to three, Principal Investigators (PIs) must partner in one overarching study in at least one of the required FY19 PRCRP Topic Areas. At least one military or VA investigator is strongly encouraged to be included as an equal partner in the research offering both intellectual investment and research effort.
  - A military or VA investigator is defined as an investigator who is active duty, active reserve, active duty detailed to agencies outside of the DoD, civilian DoD investigators, or an investigator at a VA research facility. The military/VA investigator should have a substantial role in the research and should not be included only for access to active duty military and/or VA populations (see “Relevance to Military Health” below).
- Translation: The application should provide evidence for the reciprocal transfer of information between basic and clinical science or vice versa in developing and implementing the research plan. Translational research should be based on clinical trials. The application should demonstrate how the study will leverage clinical information to address knowledge gaps in resulting outcomes, validate key research findings, and expand upon potentially translational results, or investigate novel findings.
- Relevance to Military Health: The proposed research must address at least one of the FY19 PRCRP Military Health Focus Areas. The proposed research must be relevant to active duty Service members, Veterans, and other military beneficiaries. For more information, review the following websites: PRCRP (https://cdmrp.army.mil/prcrp/default), PRCRP Report to Congress (https://cdmrp.army.mil/prcrp/reports/reports), Military Health System (MHS) (https://www.health.mil/), and VA (https://www.va.gov/oro/).
- Impact: The proposed research should have the potential to have a significant impact on cancer research and/or patient care and the potential to accelerate the movement of promising ideas (in prevention, detection, diagnosis, prognosis, treatment, and/or survivorship) into clinical applications for at least one of the FY19 PRCRP Topic Areas.
- Preliminary Data Required: Clinical data must be included in the application and/or citations of the investigators’ work that are relevant to the proposed studies.

Collaborations with a military/VA investigator are strongly encouraged. All PIs are encouraged to align their research projects with DoD and/or VA research laboratories and programs. While not a complete list, the following websites may be useful in identifying additional information about ongoing DoD and VA areas of research interest or potential opportunities for collaboration:

- Air Force Research Laboratory https://www.wpafb.af.mil/afrl
- Armed Forces Radiobiology Research Institute https://www.usuhs.edu/afrri/
- Naval Health Research Center https://www.med.navy.mil/sites/nhrc
- Office of Naval Research https://www.onr.navy.mil/
- Uniformed Services University of the Health Sciences https://www.usuhs.edu/research
- U.S. Army Medical Research Acquisition Activity https://www.usamraa.army.mil/
Cancer clinical research resources: PIs are encouraged to review clinical research and/or trial information and resources available through the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). Detailed information on the activities of the CTEP can be found at https://ctep.cancer.gov/default.htm.

A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-CancerResearch) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY19 PRCRP priorities.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 PRCRP TTSA award will not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** May 22, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 28, 2019

**Sponsor Deadline:** September 11, 2019